US20170319718A1 - Methods and devices for preparation of ultrasound contrast agents - Google Patents

Methods and devices for preparation of ultrasound contrast agents Download PDF

Info

Publication number
US20170319718A1
US20170319718A1 US15/587,368 US201715587368A US2017319718A1 US 20170319718 A1 US20170319718 A1 US 20170319718A1 US 201715587368 A US201715587368 A US 201715587368A US 2017319718 A1 US2017319718 A1 US 2017319718A1
Authority
US
United States
Prior art keywords
uca
aqueous
lipid formulation
formulation
shaking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/587,368
Other languages
English (en)
Inventor
Simon P. Robinson
Carol Walker
David C. Onthank
Joel Lazewatsky
Nhung Tuyet Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lantheus Medical Imaging Inc
Original Assignee
Lantheus Medical Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantheus Medical Imaging Inc filed Critical Lantheus Medical Imaging Inc
Priority to US15/587,368 priority Critical patent/US20170319718A1/en
Assigned to LANTHEUS MEDICAL IMAGING, INC. reassignment LANTHEUS MEDICAL IMAGING, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LAZEWATSKY, JOEL, ONTHANK, DAVID C., ROBINSON, SIMON P., WALKER, CAROL, NGUYEN, NHUNG TUYET
Publication of US20170319718A1 publication Critical patent/US20170319718A1/en
Assigned to JPMORGAN CHASE BANK, N.A. reassignment JPMORGAN CHASE BANK, N.A. PATENT SECURITY AGREEMENT Assignors: LANTHEUS MEDICAL IMAGING, INC.
Assigned to LANTHEUS MEDICAL IMAGING, INC. reassignment LANTHEUS MEDICAL IMAGING, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: JPMORGAN CHASE BANK, N.A.
Assigned to WELLS FARGO BANK, N.A. reassignment WELLS FARGO BANK, N.A. SECURITY AGREEMENT Assignors: LANTHEUS MEDICAL IMAGING, INC.
Priority to US16/559,528 priority patent/US10588988B2/en
Priority to US16/780,328 priority patent/US20200171177A1/en
Assigned to LANTHEUS MEDICAL IMAGING, INC. reassignment LANTHEUS MEDICAL IMAGING, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: WELLS FARGO BANK, N.A.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48—Diagnostic techniques
    • A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F31/00—Mixers with shaking, oscillating, or vibrating mechanisms
    • B01F31/20—Mixing the contents of independent containers, e.g. test tubes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F31/00—Mixers with shaking, oscillating, or vibrating mechanisms
    • B01F31/20—Mixing the contents of independent containers, e.g. test tubes
    • B01F31/201—Holders therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/20—Measuring; Control or regulation
    • B01F35/22—Control or regulation
    • B01F35/2201—Control or regulation characterised by the type of control technique used
    • B01F35/2207—Use of data, i.e. barcodes, 3D codes or similar type of tagging information, as instruction or identification codes for controlling the computer programs, e.g. for manipulation, handling, production or compounding in mixing plants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F35/00—Accessories for mixers; Auxiliary operations or auxiliary devices; Parts or details of general application
    • B01F35/20—Measuring; Control or regulation
    • B01F35/22—Control or regulation
    • B01F35/2201—Control or regulation characterised by the type of control technique used
    • B01F35/2209—Controlling the mixing process as a whole, i.e. involving a complete monitoring and controlling of the mixing process during the whole mixing cycle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0053—Details of the reactor
    • B01J19/0066—Stirrers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/13—Tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Definitions

  • Contrast-enhanced ultrasound imaging is a commonly used medical imaging modality.
  • Most if not all ultrasound contrast agents (UCA) are gas-filled microspheres that are useful in enhancing ultrasound signal.
  • UCA ultrasound contrast agents
  • One such UCA is activated DEFINITY® comprising perflutren lipid microspheres (i.e., perflutren gas encapsulated in lipid microspheres).
  • DEFINITY® formulation is packaged in a vial comprising lipids in an aqueous suspension with perflutren gas in the headspace. Prior to use, DEFINITY® is activated by shaking the vial vigorously, thereby forming lipid microspheres comprising perflutren gas suspended in an aqueous liquid.
  • Proper activation ensures that the microspheres formed are of the appropriate size and concentration to be both diagnostically effective and safe for the subject. Due to the importance of proper size and concentration, activation should optimally be performed in a manner that minimizes the potential for human error.
  • activation-dependent UCA formulations such as but not limited to DEFINITY® formulation
  • DEFINITY® formulation a formulation that is properly distinguished from each other and thus properly activated.
  • activation-dependent UCA formulations As additional activation-dependent UCA formulations come to market, it will be imperative to distinguish between them in order to ensure each is handled and activated in the correct prescribed manner.
  • each activation-dependent UCA will have its own unique activation parameters, including for example activation time and/or activation rate (e.g., shaking rate), and thus it will be imperative that each UCA formulation be handled in a specific manner.
  • One such new and improved UCA formulation is a non-aqueous UCA formulation, referred to herein as DEFINITY-II.
  • DEFINITY-II a non-aqueous UCA formulation
  • This UCA formulation is surprisingly more robust than earlier liquid UCA formulations. Specifically, unlike earlier liquid UCA formulations which had to be stored cold prior to use, this new non-aqueous UCA formulation is stable at room temperature for extended periods of time. Even more surprisingly, this UCA formulation can be made and used without complex manipulation. Given these added benefits, it is expected that this new non-aqueous UCA formulation will be readily adopted. The formulation is however activated for a different time period than the DEFINITY® formulation, and therefore it is important to ensure that each UCA formulation is activated for its own specific optimal period of time.
  • Activation for a different period of time can lead to microspheres that are too large, or too small, and/or of such low concentration to be clinical useful.
  • UCA aqueous DEFINITY® and non-aqueous DEFINITY-II formulations
  • this disclosure provides in one aspect, a method for forming gas-filled microspheres comprising identifying a UCA formulation, and activating the UCA formulation for a pre-determined (e.g., pre-set) period of time using a device that selects between two or more pre-determined periods of time, to form gas-filled microspheres.
  • the device may automatically select between the two or more pre-determined periods of time.
  • the means is also able to identify the UCA formulation and/or its housing (e.g., container, such as vial), and optionally distinguish such UCA formulation and/or its housing form one or more other UCA formulations or housings.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a UCA formulation, and activating the UCA formulation using a pre-determined shaking rate using a device that selects between two or more pre-determined shaking rates, to form gas-filled microspheres.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising activating a UCA formulation to form gas-filled microspheres, using a means (e.g., a device) that distinguishes an aqueous UCA formulation from a non-aqueous UCA formulation (and/or vice versa).
  • a means e.g., a device
  • the aqueous UCA formulation may be distinguished from a non-aqueous UCA formulation (or vice versa) based on the type of container including its shape or size housing such UCA formulations.
  • the means comprises a detector. In some embodiments of any of the foregoing aspects and embodiments, the means (e.g., device) is able to activate at a pre-determined period of time selected between two or more pre-determined periods of time.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a UCA formulation requiring activation for a pre-determined period of time, using a means (e.g., device) that distinguishes an aqueous UCA formulation from a non-aqueous UCA formulation, and activating the UCA formulation for a pre-determined period of time to form gas-filled microspheres.
  • a means e.g., device
  • the UCA formulation is an aqueous UCA formulation. In some embodiments of any of the foregoing aspects and embodiments, the UCA formulation is a non-aqueous UCA formulation.
  • the pre-determined period of time is a shorter period of time if the UCA formulation is an aqueous UCA formulation and a longer period of time if the UCA formulation is a non-aqueous UCA formulation. In some embodiments of any of the foregoing aspects and embodiments, the pre-determined period of time is about 45 seconds if the UCA formulation is an aqueous UCA formulation and 60-120 seconds or about 75 seconds if the UCA formulation is a non-aqueous UCA formulation.
  • the device comprises a first holder capable of holding a vial comprising an aqueous UCA formulation and incapable of holding a vial comprising a non-aqueous UCA formulation. In some embodiments of any of the foregoing aspects and embodiments, the device comprises a first holder capable of holding a vial comprising an non-aqueous UCA formulation and incapable of holding a vial comprising a aqueous UCA formulation.
  • the device distinguishes an aqueous UCA formulation from a non-aqueous UCA formulation based on a unique identifier.
  • the device comprises a detector.
  • the detector is an RFID reader and the UCA formulation is housed in a container that comprises, contains or is associated with or labeled with an RFID tag/label.
  • the detector is a barcode scanner and the UCA formulation is housed in a container that comprises, contains or is associated with or labeled with a barcode.
  • the detector is a color scanner and the UCA formulation is housed in a container that comprises a colored label.
  • the device imparts a reciprocating motion to a vial comprising the UCA formulation.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a labeled vial comprising a UCA formulation requiring activation for a pre-determined period of time, and activating the UCA formulation using a shaking device comprising a detector and set to the pre-determined period of time or capable of automatically selecting the pre-determined period of time based on the identity of the vial, to form gas-filled microspheres.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a labeled vial comprising a UCA formulation requiring activation for a pre-determined period of time, using a shaking device comprising a detector and set to the pre-determined period of time or capable of automatically selecting the pre-determined period of time based on the identity of the vial, and activating the UCA formulation to form gas-filled microspheres.
  • the labeled vial is labeled with a unique identifier.
  • the pre-determined period of time is about 45 seconds.
  • the detector is an RFID reader and the labeled vial comprises an RFID tag/label. In some embodiments of any of the foregoing aspects and embodiments, the detector is a barcode scanner and the labeled vial comprises a barcode. In some embodiments of any of the foregoing aspects and embodiments, the detector is a color scanner and the labeled vial comprises a colored label.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising activating a UCA formulation for the pre-determined period of time to form gas-filled microspheres, wherein the UCA formulation is activated using a shaking device set to activate at least two different pre-determined periods of time or capable of automatically selecting from at least two different pre-determined periods of time based on the identity of the UCA formulation.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a UCA formulation requiring activation for a pre-determined period of time, and activating the UCA formulation for the pre-determined period of time to form gas-filled microspheres, wherein the UCA formulation is activated using a shaking device set to activate at at least two different pre-determined periods of time or capable of automatically selecting from at least two different pre-determined periods of time based on the identity of the UCA formulation.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a non-aqueous UCA formulation requiring activation for a pre-determined period of time, and activating the UCA formulation for the pre-determined period of time to form gas-filled microspheres.
  • the UCA formulation is identified and activated using a shaking device set to activate at a pre-determined period of time or capable of automatically selecting a pre-determined period of time based on the identity of the UCA formulation.
  • the pre-determined period of time is about 45 seconds. In some embodiments of any of the foregoing aspects and embodiments, the pre-determined period of time is in the range of 60-120 seconds or about 75 seconds.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a non-aqueous UCA formulation requiring activation for a pre-determined first period of time, and activating said UCA formulation to form gas-filled microspheres by shaking using a shaking device capable of automatically selecting the first pre-determined period of time from at least two different pre-determined periods of time, based on identity of the UCA formulation.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a non-aqueous UCA formulation requiring activation for a pre-determined first period of time based on its container, and activating said UCA formulation to form gas-filled microspheres by shaking using a shaking device capable of automatically selecting the first pre-determined period of time from at least two different pre-determined periods of time, based on identity of the container.
  • the container is a vial.
  • the at least two different pre-determined periods of time are about 45 seconds and about 75 seconds.
  • the device such as the shaking device imparts a reciprocating motion to the container (e.g., the vial) when present in a holder.
  • the shaking device comprises a detector.
  • the detector may be an RFID reader and the vial may comprise, contain, be associated with or be labeled with an RFID tag/label.
  • the detector may be a barcode scanner and the vial may comprise, contain, be associated with or be labeled with a barcode.
  • the detector may be a color scanner and the vial may comprise, contain, be associated with or be labeled with a colored indicator.
  • the colored indicator may comprise a colored label.
  • the colored indicator may comprise a colored cap.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising activating a UCA formulation using a shaking device that identifies the UCA formulation and automatically selects an activation time based thereon, wherein the UCA formulation is identified based on a unique identifier other than shape or size of vial housing the UCA formulation.
  • This disclosure provides, in another aspect, a method for activating a first UCA formulation using a shaking device that can distinguish a container such as a vial comprising the first UCA formulation from a container such as a vial comprising a second UCA formulation.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a labeled vial comprising a UCA formulation requiring activation for a pre-determined first period of time, and activating the UCA formulation using a shaking device set to the pre-determined period of time or capable of automatically selecting the first pre-determined period of time from at least two different pre-determined periods of time, based on the identity of the vial, to form gas-filled microspheres.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a labeled vial comprising a UCA formulation requiring activation for a pre-determined first period of time, and activating the UCA formulation using a shaking device comprising a detector and set to the pre-determined period of time or capable of automatically selecting the first pre-determined period of time from at least two different pre-determined periods of time, based on the identity of the vial, to form gas-filled microspheres.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a vial comprising a UCA formulation requiring activation for a pre-determined first period of time, and activating the UCA formulation using a shaking device comprising a detector and set to the pre-determined period of time or capable of automatically selecting the first pre-determined period of time from at least two different pre-determined periods of time, based on the identity of the vial, to form gas-filled microspheres.
  • the at least two different pre-determined periods of time are about 45 seconds and about 75 seconds.
  • the method produces substantially similar gas-filled microspheres from a first vial and a second vial provided the first vial is shaken for a first period of time and the second vial is shaken for a second different period of time.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying an aqueous UCA formulation requiring activation for a pre-determined period of time, using a device that distinguishes the aqueous UCA formulation from a non-aqueous UCA formulation, and activating the aqueous UCA formulation for a pre-determined period of time to form gas-filled microspheres.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a UCA formulation requiring activation for a pre-determined period of time, and activating the UCA formulation for the pre-determined period of time to form gas-filled microspheres, wherein the UCA formulation is identified and activated using a shaking device capable of automatically selecting the pre-determined period of time from at least 2 pre-determined periods of time based on the identity of the UCA formulation.
  • the UCA formulation is an aqueous UCA formulation. In some embodiments of any of the foregoing aspects and embodiments, the UCA formulation is a non-aqueous UCA formulation. In some embodiments of any of the foregoing aspects and embodiments, an aqueous UCA formulation is activated for a shorter period of time than a non-aqueous UCA formulation. In some embodiments of any of the foregoing aspects and embodiments, the pre-determined period of time is about 45 seconds. In some embodiments of any of the foregoing aspects and embodiments, the pre-determined period of time is about 75 seconds.
  • This disclosure provides, in another aspect, a method for forming gas-filled microspheres comprising identifying a vial comprising an ultrasound contrast agent formulation requiring activation for a pre-determined first period of time using a shaking device capable of selecting the first period of time from two pre-determined periods of time, based on the identity of the vial.
  • the method is automated.
  • the two pre-determined periods of time are about 45 seconds and about 75 seconds.
  • the method produces substantially similar gas-filled microspheres from a first vial and a second vial provided the first vial is shaken for a first period of time and the second vial is shaken for a second different period of time.
  • This disclosure provides, in another aspect, a method for imaging a subject comprising administering to a subject in need thereof gas-filled microspheres prepared according to any one of the foregoing claims, and obtaining one or more images of the subject using ultrasound.
  • the device further comprises a counter that counts a number of times the device has been used, a number of times the device has shaken for a first period of time, and/or a number of times the device has shaken for a second period of time.
  • This disclosure provides, in another aspect, a device that activates a UCA formulation and that distinguishes an aqueous UCA formulation from a non-aqueous UCA formulation.
  • the device activates an aqueous UCA formulation for a shorter period of time than a non-aqueous UCA formulation.
  • a shaking device comprising a holder, means for shaking the holder, wherein the holder shakes a vial comprising a UCA formulation for different pre-determined periods of time.
  • the device further comprises means for automatically identifying the pre-determined period of time the vial must be shaken to form gas-filled microspheres.
  • the shaking device imparts a reciprocating motion to the vial when present in the holder.
  • the first pre-determined period of time is about 45 seconds. In some embodiments, the second pre-determined period of time is about 75 seconds.
  • the means for identifying the vial comprises an RFID reader which responds to a first RFID label by shaking the vial for a first period of time, and which responds to a second RFID label by shaking the vial for a second period of time, wherein the first and second periods of time are different.
  • the means for identifying the vial comprises a microchip reader which responds to a first microchip by shaking the vial for a first period of time, and which responds to a second microchip by shaking the vial for a second period of time.
  • the means for identifying the vial comprises a barcode scanner which responds to a first barcode by shaking the vial for a first period of time, and which responds to a second barcode by shaking the vial for a second period of time.
  • the RFID label, the microchip or the barcode is present on the vial.
  • the UCA formulation is a non-aqueous UCA formulation.
  • a shaking device for forming gas-filled microspheres comprising an identification means capable of identifying and distinguishing between a first vial and a second vial, each vial comprising a UCA formulation, and an automated shaking means capable of shaking for only one of at least two different pre-determined periods of time based on the identification of the vial.
  • the at least two different pre-determined periods of time are about 45 seconds and about 75 seconds.
  • the identification means comprises an RFID reader, a microchip reader, or a barcode scanner.
  • a shaking device for forming gas-filled microspheres comprising a holder capable of identifying and distinguishing between a first vial and a second vial, each vial comprising a UCA formulation, and
  • the shaking device imparts a reciprocating motion to a vial when present in the holder.
  • the first pre-determined period of time is about 45 seconds. In some embodiments, the second pre-determined period of time is about 75 seconds.
  • the holder comprises an RFID reader.
  • the holder assumes a first configuration if the first vial is present and a second configuration if a second vial is present, and wherein the first configuration indicates presence of the first vial and the second configuration indicates presence of the second vial.
  • the device further comprises a counter that counts a number of times the shaking device has been used, a number of times the shaking device has shaken for a first period of time, and/or a number of times the shaking device has shaken for a second period of time.
  • a shaking device comprising a holder capable of identifying a vial comprising a UCA formulation, and means for shaking the holder, wherein the holder is capable of shaking only for a pre-determined period of time to form gas-filled microspheres, based on the vial identity.
  • a shaking device comprising a holder, means for shaking the holder, wherein the holder is capable of shaking only for a pre-determined period of time, and means for identifying a vial comprising a UCA formulation when present in the holder and then shaking the identified vial for the pre-determined period of time to form gas-filled microspheres, wherein the means for identifying the vial comprises an RFID reader, a microchip reader, or a barcode scanner.
  • kits comprising any of the foregoing shaking devices, with instructions for activation of a UCA formulation.
  • the kit further comprises a container, such as a vial, comprising the UCA formulation.
  • the UCA formulation is a non-aqueous UCA formulation.
  • the kit further comprises the first vial or the second vial, each vial comprising a UCA formulation.
  • This disclosure provides, in another aspect, a non-transitory computer readable medium programmed with a plurality of instructions that, when executed by at least one processor of a shaking device perform a method, the method comprising: determining based, at least in part, on an identification of a sample type in a vial comprising a UCA formulation inserted into a holder of the shaking device at least one action to perform; and instructing the shaking device to perform the determined at least one action based, at least in part, on the identification.
  • a shaking device comprising: a holder configured to identify a type of sample in a vial comprising a UCA formulation inserted into the holder; at least one storage device configured to store at least one data structure identifying one or more actions to perform for each of a plurality of sample types;
  • At least one processor programmed to access the at least one data structure to determine the one or more actions to perform on the vial based on the identified sample type; and at least one component configured to perform the one or more actions determined by the at least one processor.
  • FIG. 1 is a schematic of a sample handling device and sample vial according to one aspect
  • FIG. 2 is a schematic of one embodiment of a sample handling device and sample vial
  • FIG. 3 is a schematic of a second embodiment of a sample handling device and sample vial
  • FIG. 4 is a schematic of a third embodiment of a sample handling device and sample vial
  • FIG. 5 is a flowchart of a process for determining action(s) to perform on a sample vial based on its identification according to one aspect
  • FIG. 6 is an example of the process of FIG. 5 in which the vial is identified based on an RFID tag associated with the vial;
  • FIG. 7 is a schematic diagram of a computer system that may be included as a portion of a device for processing a sample vial according to one aspect.
  • UCA formulations having one or more advantages over previously developed UCA formulations.
  • One such improved UCA formulation is a non-aqueous UCA formulation comprising lipids and a perfluorocarbon gas in a non-aqueous solution.
  • Another such improved UCA formulation is an aqueous UCA formulation comprising lipids and a perfluorocarbon gas in an aqueous solution.
  • Each of these UCA formulations provide specific advantages over existing UCA formulations including for example stability at elevated temperatures (e.g., room temperature) or enhanced safety profiles.
  • the methods and means (e.g., devices) provided herein share the unique feature of distinguishing between different activation-dependent UCA formulations. As will be described in greater detail below, each activation-dependent UCA formulation will have its own specific activation criteria (or parameters) and therefore each such UCA formulation must be activated in only a certain manner. The methods and means (e.g., devices) provided herein commonly identify and thus distinguish an activation-dependent UCA formulation from other activation-dependent UCA formulations and activate the identified UCA formulation accordingly.
  • the methods are performed and the means (e.g., devices) operated in relatively autonomous manner such that there is little risk of end user error in the activation process.
  • DEFINITY® An FDA-approved activation-dependent UCA formulation is DEFINITY®.
  • DEFINITY® is provided in a vial as an aqueous suspension of lipids with a perflutren gas headspace.
  • VIALMIX® or VIALMIX® device, as the terms are used interchangeably
  • “activated DEFINITY®” comprises a maximum of 1.2 ⁇ 10 10 perflutren lipid microspheres per ml of suspension. Activation for the wrong duration or shake speed will impact the microsphere profile, and render the UCA suboptimal or unusable in some instances.
  • improved means for activating a UCA formulation.
  • certain improved devices may comprise counters that can monitor use of the device, including lifetime use of the device, that can be useful in avoiding mechanical malfunction at critical times. They may also comprise temperature sensors that can measure the temperature of a container prior to activation. As described in greater detail herein, some of these devices may also be able to activate more than one UCA formulation, and may therefore be capable of identifying and optionally distinguishing between two or more UCA formulations.
  • the device may automatically recognize a container comprising a UCA formulation and based on such identity, which may be imparted for example by the label, shape, color or size of the container, or the optical properties of its contents, may activate the UCA formulation for a pre-determined period of time which in turn may be selected between two or more different pre-determined periods of time.
  • the device may be able to perform such recognition with no or minimal user input.
  • a UCA refers to gas-filled microspheres that are useful in enhancing ultrasound signal.
  • the UCA is provided in solution such as a pharmaceutically acceptable solution.
  • a pharmaceutically acceptable carrier Depending on the concentration of microspheres in the UCA, it may be diluted with a pharmaceutically acceptable carrier prior to administration to a subject, although this may not be required in some instances.
  • An activation-dependent UCA formulation refers to a composition that must be activated in order to form gas-filled microspheres.
  • a UCA formulation typically contains no such gas-filled microspheres (or such a low concentration of them to not be clinically useful), and must be activated in order to form microspheres of sufficient diameter and concentration to be clinically useful.
  • Activation-dependent UCA formulations typically require vigorous shaking prior to use to form gas-filled microspheres. Such activation is performed by an end user or an intermediate, but not the supplier or manufacturer of the UCA formulation.
  • Activation-dependent UCA formulations are typically packaged in vials that minimally house a lipid solution and a gas. The shaking of the lipid solution and the gas results in the formation of gas-filled microspheres that act as the contrast agent in an ultrasound imaging procedure.
  • UCA formulations of this disclosure are activation-dependent UCA formulations, and thus the terms “UCA formulation” and “activation-dependent UCA formulation” are used interchangeably.
  • gas-filled the microspheres comprise gas, such as a perfluorocarbon gas including but not limited to perflutren gas, in their internal cavity.
  • the lipid shell that encapsulates the gas may be arranged as a unilayer or a bilayer, including unilamellar or multilamellar bilayers.
  • the microspheres may have a mean diameter of less than 10 microns, or less than 6 microns, or less than 3 microns, or more preferably less than 2 microns.
  • mean diameters intend that, when a population of microspheres is analyzed, the mean diameter of the population is less than 10 microns, or less than 6 microns, or less than 3 microns, or more preferably less than 2 microns.
  • the microspheres may have a mean diameter in the range of 0.5 to 3 microns, or 1 to 2 microns, or 1.4 to 1.8 microns, or 1.4 to 1.6 microns.
  • the mean diameter may be about 1.6 microns.
  • an activation-dependent UCA formulation Prior to use, an activation-dependent UCA formulation must be shaken vigorously, to form gas-filled microspheres.
  • the microspheres may be combined with, for example, an aqueous solution prior to withdrawal from their container. This is particularly the case with microspheres made from non-aqueous UCA formulations.
  • Such a step is referred to as reconstitution, in the context of this disclosure.
  • the microspheres, whether or not reconstituted may be withdrawn from their container and combined in another solution, such as an aqueous solution, prior to administration to a subject.
  • dilution in the context of this disclosure.
  • the reconstituted population of microspheres may be used neat or after dilution in a pharmaceutically acceptable solution. Such dilution may be about 10-fold up to and about 50-fold, although it is not so limited.
  • gas-filled microspheres and lipid-encapsulated gas microspheres are used interchangeably.
  • UCA formulations minimally comprise one or more lipid types and a gas such as perfluorocarbon gas such as perflutren gas.
  • UCA formulations include aqueous UCA formulations such as DEFINITY® and non-aqueous UCA formulations such as DEFINITY-II.
  • DEFINITY® comprises lipids DPPA, DPPC and MPEG5000-DPPE, propylene glycol and glycerol in an aqueous solution together with perflutren gas.
  • DEFINITY-II comprises lipids DPPA, DPPC and MPEG5000-DPPE, and propylene glycol and glycerol together with a perfluorocarbon gas (e.g., perflutren gas).
  • a perfluorocarbon gas e.g., perflutren gas
  • DEFINITY® is an example of an aqueous UCA formulation. Activated DEFINITY® is approved by the FDA for use in subjects with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
  • DEFINITY® is provided in a vial comprising a single phase solution comprising DPPA, DPPC and MPEG5000-DPPE in a 10:82:8 mole % ratio in an aqueous solution, and a headspace comprising perfluoropropane gas. Prior to its administration to a subject, DEFINITY® is activated by vigorous shaking, such as vigorous mechanical shaking, and is thereafter referred to as “activated DEFINITY®”.
  • DPPA, DPPC and DPPE may be used in molar percentages of about 77-90 mole % DPPC, about 5-15 mole % DPPA, and about 5-15 mole % DPPE, including DPPE-MPEG5000.
  • Preferred ratios of each lipid include weight % ratios of 6.0 to 53.5 to 40.5 (DPPA:DPPC:MPEG5000-DPPE) or a mole % ratio of 10 to 82 to 8 (10:82:8) (DPPA:DPPC:MPEG5000-DPPE).
  • Non-aqueous UCA formulations comprise a non-aqueous mixture of one or more lipids and propylene glycol (PG), or glycerol (G), or propylene glycol and glycerol (PG/G). These formulations may be stored at higher temperatures (e.g., room temperature) for longer periods of time than were previously thought possible, without significant degradation.
  • the non-aqueous UCA formulations for example DEFINITY-II, may comprise less than 10%, less than 5%, or less than 2% impurities when stored at room temperature for a period of time, including for example, about 1 month, about 2 months, about 3 months, about 6 months, or longer including about 1 year, or about 2 years.
  • the non-aqueous UCA formulations may comprise fewer impurities than DEFINITY® when both formulations are stored at room temperature (i.e., when the non-aqueous UCA formulation and DEFINITY® formulation are stored at room temperature).
  • This reduction in impurity level may be a difference of about 1%, about 2%, about 3%, about 4%, or about 5%, or more.
  • the non-aqueous mixture of lipids in propylene glycol, or glycerol, or propylene glycol and glycerol may be a mixture having less than or equal to 5% water by weight (i.e., weight of water to the weight of the combination of lipids and propylene glycol and/or glycerol).
  • the non-aqueous mixture comprises less than 5% water (w/w), 1-4% water (w/w), 1-3% water (w/w), 2-3% water (w/w), or 1-2% water (w/w).
  • the non-aqueous mixture comprises less than 1% water (w/w).
  • the water content may be measured at the end of manufacture (and prior to long term storage) or it may be measured after storage, including long term storage, and just before use.
  • the non-aqueous mixture also may be salt-free intending that it does not contain any salts other than lipid counter-ions. More specifically, and as an example, lipids such as DPPA and DPPE are typically provided as sodium salts. As used herein, a salt-free non-aqueous mixture may comprise such counter-ions (e.g., sodium if DPPA and/or DPPE are used) but they do not contain other ions. In some instances, the non-aqueous mixture is free of sodium chloride or chloride.
  • the non-aqueous mixture may comprise a buffer.
  • the buffer may be an acetate buffer, a benzoate buffer, or a salicylate buffer, although it is not so limited.
  • Non-phosphate buffers are preferred in some instances due to their dissolution profiles in the non-aqueous mixtures provided herein.
  • a phosphate buffer may be used (e.g., following or concurrent with addition of aqueous diluent such as the reconstitution or dilution step, as discussed earlier).
  • the non-aqueous mixture comprises, consists of, or consists essentially of (a) one or more lipids, (b) propylene glycol, or glycerol, or propylene glycol/glycerol, and (c) a non-phosphate buffer.
  • a non-aqueous mixtures may be provided together with a gas such as a perfluorocarbon gas or they may be provided alone (i.e., in the absence of a gas).
  • a gas such as a perfluorocarbon gas
  • Such non-aqueous mixtures may be provided in single use amounts and/or in single use containers, with or without a gas. Such containers will typically be sterile.
  • the non-phosphate buffer may be, but is not limited to, an acetate buffer, a benzoate buffer, a salicylate buffer, a diethanolamine buffer, a triethanolamine buffer, a borate buffer, a carbonate buffer, a glutamate buffer, a succinate buffer, a malate buffer, a tartrate buffer, a glutarate buffer, an aconite buffer, a citrate buffer, a lactate buffer, a glycerate buffer, a gluconate buffer, and a tris buffer. It is within the skill of the ordinary artisan to determine and optimize the concentration of buffer for each buffer type.
  • DPPA, DPPC and DPPE may be used in molar percentages of about 77-90 mole % DPPC, about 5-15 mole % DPPA, and about 5-15 mole % DPPE, including DPPE-PEG5000.
  • Preferred ratios of each lipid include weight % ratios of 6.0 to 53.5 to 40.5 (DPPA:DPPC:MPEG5000-DPPE) or a mole % ratio of 10 to 82 to 8 (10:82:8) (DPPA:DPPC:MPEG5000-DPPE).
  • the lipid concentration may range from about 0.1 mg to about 20 mg per mL of non-aqueous mixture, including about 0.9 mg to about 10 mg per mL of non-aqueous mixture and about 0.9 mg to about 7.5 mg per mL of non-aqueous mixture. In some embodiments, the lipid concentration may range from about 0.94 mg to about 7.5 mg lipid per mL of non-aqueous mixture, including about 1.875 mg to about 7.5 mg lipid per mL of non-aqueous mixture, or about 3.75 mg to about 7.5 mg lipid per mL of non-aqueous mixture.
  • the lipid concentration is about 0.94 mg to about 1.875 mg per mL of non-aqueous mixture, about 1.875 mg to about 3.75 mg per mL of non-aqueous mixture, or about 3.75 mg to about 7.5 mg of total lipid per mL of non-aqueous mixture.
  • the lipid concentration may range from about 0.1 mg to about 10 mg lipid per mL of propylene glycol/glycerol (combined), including about 1 mg to about 5 mg lipid per mL of propylene glycol/glycerol (combined). In some instances, the lipid concentration is about 0.94 mg to about 3.75 mg lipid per mL of propylene glycol/glycerol (combined).
  • the lipid concentration may range from about 0.1 mg to about 20 mg lipid per mL of propylene glycol, including about 1 mg to about 10 mg lipid per mL of propylene glycol, or about 2 mg to about 7.5 mg lipid per mL of propylene glycol, or about 3.75 mg to about 7.5 mg lipid per ml of propylene glycol. In some embodiments, the lipid concentration is about 1.875 mg to about 7.5 mg lipid per mL of propylene glycol, including about 3.75 mg to about 7.5 mg lipid per mL of propylene glycol.
  • the lipid concentration may range from about 0.1 mg to about 20 mg lipid per mL of glycerol, including about 1 mg to about 10 mg lipid per mL glycerol, or about 2 mg to about 7.5 mg lipid per mL of glycerol, or about 3.75 mg to about 7.5 mg lipid per ml of glycerol. In some instances, the lipid concentration is about 1.875 mg to about 7.5 mg lipid per mL of glycerol, including about 3.75 mg to about 7.5 mg lipid per mL of glycerol.
  • DEFINITY-II comprises lipids DPPA, DPPC and MPEG5000-DPPE at a mole % ratio of 10 to 82 to 8 (10:82:8) and a total lipid content of 3.75 mg/mL, and propylene glycol (517.5 mg/mL), glycerol (631 mg/mL), Sodium acetate (0.370 mg/mL), Acetic acid (0.030 mg/mL) together with a perfluoropropane (Perflutren) gas headspace (6.52 mg/mL).
  • Perflutren perfluoropropane
  • the microspheres may be reconstituted or diluted in an aqueous diluent, and such aqueous diluent may comprise salts such as but not limited to sodium chloride, and thus may be regarded as a saline solution.
  • the aqueous diluent may comprise a buffer such as a phosphate buffer, and thus may be regarded as a buffered aqueous diluent.
  • the aqueous diluent may be a buffered saline solution.
  • the non-aqueous mixture may comprise a buffer such as a non-phosphate buffer, examples of which are provided herein.
  • the non-aqueous mixture and the aqueous diluent may both comprise a buffer.
  • either the non-aqueous mixture or the aqueous diluent comprises a buffer, but not both.
  • the buffer concentration will vary depending on the type of buffer used, as will be understood and within the skill of the ordinary artisan to determine.
  • the buffer concentration in the non-aqueous lipid formulation may range from about 1 mM to about 100 mM. In some instances, the buffer concentration may be about 1 mM to about 50 mM, or about 1 mM to about 20 mM, or about 1 mM to about 10 mM, or about 1 mM to about 5 mM, including about 5 mM.
  • the final formulation to be administered, typically intravenously, to a subject including a human subject may have a pH in the range of 4-8 or in a range of 4.5-7.5.
  • the pH may be in a range of about 6 to about 7.5, or in a range of 6.2 to about 6.8.
  • the pH may be about 6.5 (e.g., 6.5+/ ⁇ 0.5 or +/ ⁇ 0.3).
  • the pH may be in a range of 5 to 6.5 or in a range of 5.2 to 6.3 or in a range of 5.5 to 6.1 or in a range of 5.6 to 6 or in a range of 5.65 to 5.95.
  • the pH may be in a range of about 5.7 to about 5.9 (e.g., +/ ⁇ 0.1 or +/ ⁇ 0.2 or +/ ⁇ 0.3 either or both ends of the range). In another instance, the pH may be about 5.8 (e.g., 5.8 +/ ⁇ 0.15 or 5.8 +/ ⁇ 0.1).
  • the aqueous diluent comprises glycerol, a buffer such as phosphate buffer, salt(s) and water. Such an aqueous diluent may be used with a non-aqueous mixture that lacks glycerol.
  • the lipid solution further comprises saline (salt(s) and water combined) and glycerol in a weight ratio of 8:1.
  • the aqueous diluent comprises propylene glycol, a buffer such as phosphate buffer, salt(s) and water.
  • a buffer such as phosphate buffer
  • salt(s) such an aqueous diluent may be used with a non-aqueous mixture that lacks propylene glycol.
  • the aqueous diluent comprises a buffer such as phosphate buffer, salt(s) and water.
  • a buffer such as phosphate buffer, salt(s) and water.
  • Such an aqueous diluent may be used with a non-aqueous mixture that comprises both propylene glycol and glycerol.
  • microspheres may be reconstituted and used directly (neat) or they may be reconstituted and diluted. Reconstitution and dilution involve combining the microspheres with an aqueous solution, such as a pharmaceutically acceptable solution. Either step or both together may yield microsphere concentrations of at least 1 ⁇ 10 7 microspheres per ml of solution, or at least 5 ⁇ 10 7 microspheres per ml of solution, or at least 7.5 ⁇ 10 7 microspheres per ml of solution, or at least 1 ⁇ 10 8 microspheres per ml of solution, or at least 1 ⁇ 10 9 microspheres per ml of solution, or about 5 ⁇ 10 9 microspheres per ml of solution.
  • microsphere concentration may be, in some instances, 1 ⁇ 10 7 to 1 ⁇ 10 10 microspheres per ml of solution, and more typically 5 ⁇ 10 7 to 5 ⁇ 10 9 microspheres per ml of solution.
  • a reconstituted population of microspheres may be further diluted about 10-fold up to and about 50-fold, without limitation.
  • activation of the non-aqueous UCA formulation followed by reconstitution yields about 4-5 ⁇ 10 9 microspheres per ml of solution, which may be diluted about 10 fold to yield about 4-5 ⁇ 10 8 microspheres per ml of solution.
  • DEFINITY-II is contemplated for use in a manner identical to that of DEFINITY®.
  • DEFINITY-II may be used in subjects with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, among other imaging applications.
  • aqueous UCA formulations are now being developed. Some new aqueous UCA formulations comprise, relative to DEFINITY®, a smaller volume of aqueous lipid solution (i.e., the aqueous solution comprising lipids) and a larger gas headspace. Other new aqueous UCA formulations comprise, relative to DEFINITY®, a lower lipid concentration in the aqueous solution. And still other aqueous UCA formulations are provided in containers of various shape and size (and thus volume), relative to DEFINITY®. All of these new aqueous UCA formulations can be activated to yield gas-filled microspheres on par with activated DEFINITY®, including mean diameter profile, without compromising the acoustic properties of the microspheres.
  • lipid-encapsulated gas microspheres suitable for clinical use using substantially less lipid by reducing either the volume of lipid solution or the lipid concentration is beneficial for a number of reasons, including reducing material wastage and the likelihood of overdosing a subject.
  • the choice of container would allow the end user to select the most convenient shape and size (volume) for their desired application.
  • An example of one such new aqueous UCA formulation comprises lipids DPPA, DPPC and PEG5000-DPPE (where PEG5000 includes without limitation hydroxy-PEG5000 or MPEG5000) in an aqueous solution together with a perfluorocarbon gas (e.g., perflutren gas) in a container, wherein the perfluorocarbon gas occupies about 60-85% of the container volume.
  • a perfluorocarbon gas e.g., perflutren gas
  • DEFINITY® in contrast, is provided in a container (i.e., a vial) wherein the perfluorocarbon gas (i.e., perflutren gas) occupies about 54% of the container volume.
  • DEFINITY-IV comprises an aqueous lipid solution comprising about 0.1 mg to about 0.6 mg of DPPA, DPPC and PEG5000-DPPE (combined) per ml of solution, and a perfluorocarbon gas, in a container.
  • UCA formulations are vigorously shaken to form gas-filled microspheres which will typically be used as UCA.
  • gas-filled microspheres may be formed directly or they may be formed through a process that involves formation of microspheres and incorporation of gas into such microspheres.
  • Activation is typically carried out by vigorously shaking of a container (e.g., a vial) comprising a UCA formulation.
  • the UCA formulation minimally comprises lipids and gas, and thus activation minimally results in gas-filled lipid microspheres.
  • activation comprises shaking an aqueous solution comprising a lipid in the presence of a gas, such as a perfluorocarbon gas (e.g., perflutren).
  • a gas such as a perfluorocarbon gas (e.g., perflutren).
  • activation comprises shaking a non-aqueous solution comprising a lipid in the presence of a gas, a perfluorocarbon gas (e.g., perflutren). It is to be understood that perflutren, perflutren gas and octafluoropropane are used interchangeably herein.
  • Shaking refers to a motion that agitates a solution, whether aqueous or non-aqueous, such that gas is introduced from the local ambient environment within the container (e.g., vial) into the solution. Any type of motion that agitates the solution and results in the introduction of gas may be used for the shaking.
  • the shaking must be of sufficient force or rate to allow the formation of foam after a period of time.
  • the shaking is of sufficient force or rate such that foam is formed within a short period of time, as prescribed by the particular UCA formulation.
  • such shaking occurs for about 30 seconds, or for about 45 seconds, or for about 60 seconds, or for about 75 seconds, or for about 90 seconds, or for about 120 seconds, including for example for 30 seconds, or for 45 seconds, or for 60 seconds, or for 75 seconds, or for 90 seconds, or for 120 seconds.
  • the activation may occur for a period of time in the range of 60-120 seconds, or in the range of 90-120 seconds.
  • the shaking time (or duration) will vary depending on the type of UCA formulation being activated.
  • an aqueous UCA formulation may be shaken for shorter periods of time than a non-aqueous UCA formulation.
  • the shaking rate (or shaking speed, as those terms are used interchangeably herein) may be constant.
  • an activation or shaking means such as an activation or shaking device may be set to shake at one rate (defined in terms of number of shaking motions per minute, for example) for two or more different pre-determined periods of time.
  • the disclosure further contemplates that, in some instances, the shaking rate will vary depending on the type of UCA formulation being activated.
  • an aqueous UCA formulation may be shaken at a slower shaking rate than a non-aqueous UCA formulation.
  • the shaking time (or duration, as those terms are used interchangeably herein) may be constant.
  • an activation or shaking means such as an activation or shaking device may be set to shake at two or more different pre-determined shaking rates (defined in terms of number of shaking motions per minute, for example) for one set period of time.
  • the shaking time and the shaking rate will vary depending on the type of UCA formulation being activated.
  • an aqueous UCA formulation may be shaken for a first period of time at a first shaking rate and a non-aqueous UCA formulation may be shaken for a second period of time at a second shaking rate, and the first and second periods of time may be different and the first and second shaking rates may be different.
  • an activation or shaking means such as an activation or shaking device may be set to shake at two or more different pre-determined shaking rates (defined in terms of number of shaking motions per minute, for example) for two or more different pre-determined periods of time.
  • an activation or shaking means such as an activation or shaking device may be set to shake at (1) a first pre-determined shaking rate for a first pre-determined period of time and (2) a second pre-determined shaking rate for a second pre-determined period of time, and the first and second periods of time are different and the first and second shaking rates are different.
  • DEFINITY® activation requires vigorous shaking for about 45 seconds with a VIALMIX®. Unless indicated otherwise, the term “about” with respect to activation time intends a time that is +/ ⁇ 20% of the noted time (i.e., 45+/ ⁇ 9 seconds).
  • DEFINITY-II may be activated with a VIALMIX® for periods of time ranging from 60 to 120 seconds. In some instances, DEFINITY-II is activated for about 75 seconds (i.e., 75+/ ⁇ 15 seconds). DEFINITY-II may be activated for longer periods of time including 90-120 seconds
  • the shaking may be by swirling (such as by vortexing), side-to-side, or up and down motion. Further, different types of motion may be combined.
  • the shaking may occur by shaking the container (e.g., the vial) holding the aqueous or non-aqueous lipid solution, or by shaking the aqueous or non-aqueous solution within the container (e.g., the vial) without shaking the container (e.g., the vial) itself. Shaking is carried out by machine in order to standardize the process. Mechanical shakers are known in the art and their shaking mechanisms or means may be used in the devices of the present disclosure. Examples include amalgamators such as those used for dental applications.
  • Vigorous shaking encompasses at least 1000, at least 2000, at least 3000, at least 4000, at least 4500, at least 5000 or more shaking motions per minute.
  • vigorous shaking includes shaking in the range of 4000-4800 shaking motions per minute.
  • VIALMIX® for example targets shaking for 4530 “figure of eight” revolutions per minute, and tolerates shaking rates in the range of 4077-4756 revolutions per minute.
  • Vortexing encompasses at least 250, at least 500, at least 750, at least 1000 or more revolutions per minute. Vortexing at a rate of at least 1000 revolutions per minute is an example of vigorous shaking, and is more preferred in some instances. Vortexing at 1800 revolutions per minute is most preferred.
  • the shaking rate can influence the shaking duration needed.
  • a faster shaking rate will tend to shorten the duration of shaking time needed to achieve optimal microbubble formation.
  • shaking at 4530 rpm for a 45 second duration will achieve 3398 total revolutions on a VIALMIX®.
  • Shaking at 3000 rpm would require 68 seconds to achieve the same number of revolutions. It will also be understood, therefore, that a slower shaking rate will tend to lengthen the duration of shaking time needed to achieve optimal microbubble formation.
  • the duration and shake speed required will also be influenced by the shape of the travel path and amplitude of shaking. The velocity the liquid in the container reaches and the forces exerted upon change of direction will influence gas incorporation.
  • Water has a viscosity of approximately 1.14 cps at 15° C. (Khattab, I. S. et al., Density, viscosity, surface tension, and molar volume of propylene glycol+water mixtures from 293 to 323 K and correlations by the Jouyban-Acree model Arabian Journal of Chemistry (2012).
  • propylene glycol has a viscosity of 42 cps at 25° C.
  • gas-filled microspheres upon activation can be detected by the presence of a foam on the top of the aqueous or non-aqueous solution and the solution becoming white.
  • gel state to liquid crystalline state phase transition temperature it is meant the temperature at which a lipid layer (such as a lipid monolayer or bilayer) will convert from a gel state to a liquid crystalline state. This transition is described for example in Chapman et al., J. Biol. Chem. 1974 249, 2512-2521.
  • the gel state to liquid crystalline state phase transition temperatures of various lipids will be readily apparent to those skilled in the art and are described, for example, in Gregoriadis, ed., Liposome Technology, Vol.
  • Vigorous shaking can cause heating of the formulation based on the shake speed, duration, shaker arm length and path, the container shape and size, the fill volume and the formulation viscosity.
  • the lipid(s) or lipid microspheres may be manipulated prior to or subsequent to being subjected to the methods provided herein.
  • the gas-filled microspheres may be extracted from their container (e.g., vial).
  • Extraction may be accomplished by inserting a needle of a syringe or a needle-free spike (e.g., PINSYNC®) into the container, including into the foam if appropriate, and drawing a pre-determined amount of liquid into the barrel of the syringe by withdrawing the plunger or by adding an aqueous liquid, mixing and drawing a pre-determined amount of liquid into the barrel of the syringe by withdrawing the plunger.
  • the gas-filled microspheres may be filtered to obtain microspheres of a substantially uniform size.
  • the filtration assembly may contain more than one filter which may or may not be immediately adjacent to each other.
  • this disclosure provides various methods for forming gas-filled microspheres.
  • these methods minimally comprise activating an activation-dependent UCA formulation to form gas-filled microspheres.
  • Activation may be performed using an activation means (e.g., a shaking device).
  • Such means may be capable of activation alone or it may be capable of identification of a UCA formulation (or its container) and activation of such formulation.
  • some methods comprise identifying a UCA formulation and then activating such UCA formulation based on its identity.
  • a single means e.g., device
  • different means may be use to perform each step.
  • a means may be used to activate the formulation.
  • these methods comprise activating an activation-dependent UCA formulation to form gas-filled microspheres using means (e.g., a device) that identifies a non-aqueous UCA formulation.
  • Identification of a non-aqueous UCA formulation may involve reading a label specific to a non-aqueous UCA formulation.
  • the means may be set to hold and activate the non-aqueous UCA formulation for a pre-determined period of time. In some embodiments, such pre-determined period of time is about 75 seconds.
  • these methods comprise activating an activation-dependent UCA formulation to form gas-filled microspheres using a means that distinguish a non-aqueous UCA formulation from an aqueous UCA formulation (or alternatively, a means that distinguish an aqueous UCA formulation from a non-aqueous UCA formulation).
  • An aqueous UCA formulation is an aqueous solution comprising one or more lipid(s) and a gas. Upon activation, the lipids and gas together form the gas-filled microspheres. Examples of an aqueous UCA formulation are DEFINITY®, DEFINITY-III, and DEFINITY-IV.
  • a non-aqueous UCA formulation is a non-aqueous solution comprising one or more lipid(s) and a gas. Upon activation, the lipids and gas together form the gas-filled microspheres although in this case the microspheres are surrounded by a non-aqueous solution.
  • An example of a non-aqueous UCA formulation is a room temperature stable formulation referred to herein as DEFINITY-II. As described in greater detail herein, DEFINITY-II minimally comprises lipids DPPA, DPPC and PEG5000-DPPE in propylene glycol and glycerol, along with a buffer and octafluoropropane (perflutren) gas.
  • PEG5000 refers to PEG having a molecular weight of 5000 Daltons. It may be hydroxy-PEG or methoxy-PEG.
  • DEFINITY-II comprises MPEG5000-DPPE
  • examples of non-aqueous UCA formulations comprise, for example, lipids DPPA, DPPC and MPEG5000-DPPE, propylene glycol, glycerol, a buffer, and octafluoropropane (perflutren) gas; or lipids DPPA, DPPC and MPEG5000-DPPE, propylene glycol, a buffer, and octafluoropropane (perflutren) gas; or lipids DPPA, DPPC and MPEG5000-DPPE, glycerol, a buffer, and octafluoropropane (perflutren) gas; or lipids DPPA, DPPC and MPEG5000-DPPE, propylene glycol, glycerol,
  • the gas-filled microspheres similarly comprise a DPPA/DPPC/MPEG5000 DPPE lipid shell that encapsulates the perflutren gas.
  • These microspheres are diluted in an aqueous solution, such as an aqueous saline solution and then administered to a subject, either as a bolus or continuous infusion injection.
  • these aqueous and non-aqueous UCA formulations have different optimal activation times in order to obtain diagnostically suitable gas-filled microspheres.
  • the shaking rate is about 4530 shaking motions (e.g., figure of 8 motions) per minute and shaking is performed using a VIALMIX®
  • some aqueous UCA formulations, including DEFINITY® are activated in about 45 seconds while the non-aqueous UCA formulation DEFINITY-II is activated in 60-120 seconds and in some instances in about 75 seconds in order to achieve a substantially similar microsphere profile with respect to size distribution.
  • the methods provided herein therefore facilitate the differentiation of a non-aqueous UCA formulation from aqueous UCA formulations such as DEFINITY®.
  • Other methods provided herein comprise identifying a labeled vial comprising a UCA formulation requiring activation for a pre-determined period of time using a shaking device comprising a detector and set to the pre-determined period of time or capable of automatically selecting the pre-determined period of time based on the identity of the vial, and activating the UCA formulation to form gas-filled microspheres.
  • the pre-determined period of time may be 45 seconds or it may be 75 seconds, although it is not so limited.
  • aqueous UCA formulations such as for example DEFINITY®, DEFINITY-III and DEFINITY-IV
  • the two or more aqueous UCA formulations may be differentiated based on their fill volume (i.e., the amount of liquid in their respective containers), or based on container shape and size. Fill volumes may be assessed, for example, using optical approaches (e.g., measuring absorbance of light by the formulation at a particular position along the length of the container). Container shape and size may be assessed, for example, using the holder which holds the container.
  • an aqueous UCA formulation may then be activated for its prescribed period of time and using its prescribed shaking rate.
  • the activation means e.g., the shaking device
  • the activation means may be set to shake at a pre-determined period of time, or it may be set to shake for two or more different pre-determined periods of time and would therefore be capable of automatically selecting one such period of time.
  • Such means may comprise a detector. Similar methods are provided for differentiating and optionally activating non-aqueous UCA formulations. Similar methods are provided for differentiating between aqueous and non-aqueous UCA formulations, and optionally activating one or both UCA formulations.
  • Other methods provided herein comprise identifying an aqueous UCA formulation requiring activation for a pre-determined period of time, using a device that distinguishes the aqueous UCA formulation from a non-aqueous UCA formulation, and activating the aqueous UCA formulation for the pre-determined period of time to form gas-filled microspheres.
  • Other methods provided herein comprise identifying a UCA formulation requiring activation for a pre-determined period of time, using a device that distinguishes a non-aqueous UCA formulation from an aqueous UCA formulation (or vice versa), and activating the UCA formulation for a pre-determined period of time to form gas-filled microspheres.
  • the device may be set to activate for only one pre-determined period of time (e.g., about 45 seconds if an aqueous UCA or about 75 seconds if a non-aqueous UCA), or it may be set to activate for two or more different pre-determined periods of time (e.g., about 45 seconds and about 75 seconds). It is to be understood that where two or more pre-determined periods of time are contemplated, such periods of time are different from each other.
  • Still other methods comprise identifying a UCA formulation requiring activation for a pre-determined period of time, and activating the UCA formulation for the pre-determined period of time to form gas-filled microspheres.
  • the methods comprise identifying a non-aqueous UCA formulation requiring activation for a pre-determined period of time, and activating the non-aqueous UCA formulation for the pre-determined period of time to form gas-filled microspheres.
  • the UCA formulation may be identified and activated using a shaking device set to the pre-determined period of time or capable of automatically selecting the pre-determined period of time based on the identity of the UCA formulation.
  • the methods comprise identifying a UCA formulation requiring activation for a pre-determined period of time, and activating the UCA formulation for the pre-determined period of time to form gas-filled microspheres using a shaking device that is set to two or more pre-determined periods of time or capable of automatically selecting between two pre-determined periods of time based on the identity of the UCA formulation.
  • the identity of the UCA formulation is provided by a label or tag on the container (e.g., vial) housing the formulation.
  • the identity of the UCA formulation is provided by the formulation itself or its volume, as described herein in more detail.
  • the UCA formulation may be an aqueous UCA formulation or it may be a non-aqueous UCA formulation.
  • the pre-determined period of time may be about 45 seconds.
  • the pre-determined period of time may be in the range of 60-120 seconds or about 75 seconds.
  • other methods provided herein comprise identifying a labeled vial comprising a UCA formulation requiring activation for a fixed period of time and a pre-determined shake speed using a shaking device comprising a scanner set to the fixed period of time and pre-determined shake speed or capable of automatically selecting the pre-determined shake speed based on the identity of the vial, and activating the UCA formulation to form gas-filled microspheres.
  • the pre-determined shake speed may be about 4530 rpm.
  • Still other methods comprise activating a UCA formulation using a shaking device that identifies the UCA formulation and automatically selects an activation time or shake speed (or shake rate, and the terms are used interchangeably herein) or both based thereon, wherein the UCA formulation is identified based on a unique identifier other than shape or size of a vial housing the UCA formulation.
  • Other methods comprise activating a first UCA formulation using a shaking device that can distinguish a first vial comprising the first UCA formulation from a second vial comprising a second UCA formulation.
  • Yet other methods comprise identifying a labeled vial comprising an aqueous UCA formulation requiring activation for a pre-determined first period of time, using a shaking device comprising a scanner and set to the pre-determined period of time or capable of automatically selecting the first pre-determined period of time from two pre-determined periods of time, based on the identity of the vial, and activating the UCA formulation to form gas-filled microspheres.
  • the devices first identify the vial containing the UCA formulation and provide a prompt to the user to confirm the identification. In other instances, the devices identify and activate without any user input.
  • Identification of a UCA formulation and/or distinction between different UCA formulations can be achieved in a number of ways.
  • devices may be used with scanners able to read labels on the UCA formulation container (e.g., vial).
  • identification and/or distinction between different UCA formulations can be achieved using devices that recognize the shape and size of a container housing an aqueous UCA formulation versus a container housing a non-aqueous UCA formulation. These latter devices may comprise a single holder or they may comprise two or more holders.
  • the holder may be capable of holding a container (e.g., a vial) housing a non-aqueous UCA formulation and incapable of holding a container (e.g., vial) housing an aqueous UCA formulation.
  • the holder may be capable of holding a container (e.g., a vial) housing an aqueous UCA formulation and incapable of holding a container (e.g., vial) housing a non-aqueous UCA formulation.
  • a device receives a container holding a UCA formulation, detects the UCA formulation type and performs different actions depending on the type of UCA formulation that is detected.
  • the device associates certain actions with each UCA formulation type. After detecting a certain UCA formulation type, the device automatically performs the actions associated with that UCA formulation type.
  • the device shakes the sample.
  • the device performs a specific shaking duration, pattern, and/or rate depending on the sample type that is detected. Examples of different shaking patterns include but are not limited to: side to side reciprocation, up and down reciprocation, vibration, a spinning motion, a figure-eight path, a circular path and back-and-forth tilting (e.g. rotating the container by some angle and reversing the action).
  • the device associates a shaking duration of about 45 seconds with sample type “A” and about 75 seconds with sample type “B.”
  • the device detects a sample type “A”
  • the device automatically shakes the sample for about 45 seconds without requiring the user to input a shaking time.
  • the device detects a sample type “B”
  • the device automatically shakes the sample for about 75 seconds.
  • this disclosure further contemplates devices that are capable of varying one or more parameters upon identification (and thus differentiation) of sample types.
  • one device may shake with the same pattern and at the same shaking rate for all sample types, but may shake different sample types for different durations (i.e., different shaking times).
  • one device may shake with the same pattern and for the same time for all sample types, but may shake different sample types at different rates (i.e., different shaking rates).
  • one device may shake with the same shaking rate and for the same time for all sample types, but may shake different sample types with different shaking patterns.
  • the device may respond to each sample type identified by setting, including potentially altering, two parameters, such as shaking rate and shaking time, or shaking rate and shaking pattern, or shaking time and shaking pattern.
  • the device may respond to each sample identified by setting, including potentially altering, all three of these parameters (i.e., shaking rate, shaking time, and shaking pattern).
  • adjusting temperature settings adjusting humidity settings
  • adjusting light settings e.g. subjecting the sample to different intensities and/or frequencies of light
  • inputting different substances into the container e.g. reagents, dyes or other suitable additives.
  • the container holding the sample includes an indicator that indicates the sample type and the device include a detector that reads the indicator to detect the sample type.
  • the indicator may be one that is machine- or device readable. Examples of machine- or device-readable indicators include magnetic stripes, chips/microchips, barcodes including linear, matrix and 2D barcodes, radio frequency identification (RFID) tags, color labels that are identifiable by color detection, and the like. Barcodes such as linear barcodes may be those that comply with or meet Uniform Code Council standards or Health Industry Business Communications Council standards. Such indicators may in turn be read, for example, from a device such as a magnetic stripe reader, a chip reader, a barcode scanner or reader, an RFID tag reader, and the like. Virtually any labeling technology that has been used for authentication and/or “track and trace” purposes may be used in conjunction with the containers provided herein.
  • the indicator may be positioned on any suitable portion of the sample container, such as the body of the container or the cap.
  • the indicator is integrally formed with or otherwise a part of the sample container.
  • the indicator may be a colored cap or a physical feature such as a protrusion or an indentation on the sample container.
  • the indicator is attached to the container via, for example, adhesive, magnets, hook-and-loop type fasteners, mechanical arrangement such as sliding the indicator behind holding tabs, or any other suitable attachment arrangement.
  • the indicator may provide the end user or an intermediate handler of the container a variety of information including but not limited to source and/or producer of the formulation contained therein, including for example the name of the company or company subsidiary that made the formulation and/or that produced components of the formulation, the date on which the formulation was made, the physical location where the formulation was made, the date of shipment of the container, the treatment of the container including for example whether it was stored in a remote location and the conditions and length of such storage, the date on which the container was delivered, the means of delivery, the National Drug Code (NDC) as prescribed by the FDA, content of the container, dose and method of use including route of administration, etc.
  • NDC National Drug Code
  • the indicator may serve one or more purposes including for example authentication of the container and the formulation contained therein. Authentication means the ability to identify or mark the container as originating and having been made by an authorized party, and it allows an end user or other party to identify container and formulations originating from another, unauthorized party.
  • the indicator may also be used to track and trace a container. This feature can be used to follow a container and the formulation contained therein following production and up to the point of administration to a subject. In this regard, the movement of the container during that period of time may be stored in a database, and optionally such a database may be accessible to an end user to ensure the integrity of the formulation.
  • the indicator may also be a combined indicator, intending that it may contain information that is read using two different modes.
  • the indicator may contain information that is apparent and understandable to the visible eye (e.g., it may recite the name of the producer in words) and other information that is machine-readable, such as RFID embedded or barcode embedded information.
  • the indicator may also be a dual use indicator, intending that it may serve two or more purposes.
  • the indicator may contain information that identifies the formulation and further information that identifies the manufacturer and/or date of manufacture. This information may be conveyed in the same format or using different format (e.g., one may be provided in an RFID indicator and the other may be provided in a barcode label).
  • the label may also be capable of having information recorded on it (e.g. using RFID technology) by the device used to shake the vial. For example such information may be used to prevent re-activation of the vial by any appropriately equipped device if it has previously been shaken and is now beyond the expiry period for re-activation of previously-activated vials.
  • the indicator may provide content that is visible and understandable to a human, such as for example the name of the manufacturer.
  • the indicator may contain information that while readily visible to the human eye nevertheless provides no meaningful information in the absence of a lookup table or other form of database to which reference must be made. Such information for example may be provided as alpha-numeric code.
  • the UCA formulation is in a container, such as a vial, and such container is labeled.
  • the container may have an indicator in the form of a label that is affixed to one or more of its outer surfaces.
  • the indicator is a paper label or other such label that is visible by eye and capable of being read and understood by an end user without further aid or device.
  • the indicator is one that is machine- or device readable.
  • the device may include any suitable detector for reading the indicator.
  • the detector may operate via visual, photographic, imaging, electromagnetic, visible light, infrared and/or ultraviolet modalities.
  • the indicator is a barcode and the detector is a barcode scanner.
  • the indicator is an RFID tag and the detector is an RFID reader.
  • the indicator is a colored label and the detector is a color detecting scanner.
  • the indicator is a chip/microchip and the detector is a chip/microchip reader.
  • the sample containers include an indexing feature that ensures that the indicator on the container is properly aligned with the detector on the device.
  • indexing features include physical recesses or protrusions on the container cap or body that align with corresponding features on the holder such that the container can only fit into the holder in one orientation.
  • the indicator is a physical component, such as a protrusion or an indentation on the container.
  • the detector is a button on the device that is pushed or a sensor that is otherwise activated due to physical interaction with the physical component.
  • the indicator is a specifically shaped protruding tab on the cap of the sample container, and the device includes corresponding slots into which the tabs can be inserted. Each sample type is associated with a specific tab shape, and each tab shape exclusively fits with only one of the slots on the device.
  • An L-shaped tab is associated with sample type “A,” and an oval-shaped tab is associated with sample type “B.”
  • the portion of the device that interacts with the container cap has associated slots; one that receives the L-shaped tab and one that receives the oval-shaped tab.
  • the device is able to detect the sample type based on one or more properties of the sample container.
  • properties include weight, optical properties, and size of the container.
  • the weight of the sample may reflect a sample type.
  • containers having samples of type A may have one weight range and containers having samples of type B may have a second, different weight range.
  • the device may include a scale or other weight detection apparatus that determines the combined weight of the container and sample. If the weight falls within the first range, the device determines that the sample is type A and if the weight falls within the second range, the device determines that the sample is type B.
  • the weight detection apparatus may be integrated into the holder or may be a separate weighing station on the device. In the case of a separate weighing station, the user places the container in/on the weight detection apparatus, the device measures the weight to detect the sample type, and then the user or the device itself moves the sample container to the holder.
  • each sample type may be associated with a known optical property.
  • optical properties include but are not limited to index of refraction, absorption and fluorescence.
  • the device may include a suitable instrument for measuring the optical property and, from the measurement, determine the associated sample type.
  • each sample type may be associated with a different sized container.
  • sample type “A” may have a container that is larger than the container used for sample type “B.”
  • the device may detect container size in variety of ways.
  • the device has more than one holder—each holder being sized to accommodate one of the sample container sizes.
  • Each sample container size may only fit into one of the holders.
  • the device detects when and which holder has received a container. By knowing which holder has a container, the device determines the sample container size and the sample type associated with that container size.
  • the device has a single holder that can accommodate differently-sized containers.
  • the holder may have a spring-biased end that can be moved to different positions to accommodate larger containers.
  • the device may have buttons or other sensors that detect the receipt of a container and the size at which the holder has been enlarged to in order to determine the container size.
  • the user may need to manually adjust the holder size by removing filler pieces, flipping open doors, or otherwise moving components to size the holder to appropriately and snugly accommodate the sample container.
  • the device would then sense the size of the holder and determine the container size accordingly.
  • the device may include visual detectors such as a camera and/or a laser to detect the size of the container.
  • a camera may take an image of the container and process the image to determine the size of the container.
  • a laser may be directed to a position that would hit the container if a large-sized container is used but pass through nothing if a small-sized container is used, and the device would accordingly detect the container size by determine whether the laser had been obstructed or otherwise interfered with along its path.
  • the device may have a variety of different features to aid in operation.
  • the device may include a counting feature that can track how many times the machine has been used to conduct certain actions.
  • a counting device may track the number of revolutions/oscillations the shaking device has performed. Such a feature may be used for maintenance anticipation and monitoring of device performance.
  • the counter may be digital or manual.
  • the counter may be used to track how many times a specific sample has been acted upon, e.g., the counter may track how many times a specific container/vial has been activated.
  • the counter may be used to generally track how many of each type of sample has been received and acted upon.
  • the device may include a display that can communicate a variety of different messages to a user.
  • the display may indicate the status of the device, errors, sample type, and may alert the user to any potential problems.
  • Alerts may be auditory and/or visual. Examples of alerts include: alerting the user that a specific action has been performed on a sample a certain number of times, that an action has not been performed adequately or has been performed too much (e.g. shaking time was too long or too short), that the cover is open, that the container is not seated appropriately in the holder, and/or that the device requires or is soon to require maintenance.
  • the device will alert a user that the action that has been performed on the sample or container (e.g., vial) exceeded or is near the limits of an acceptable range.
  • the device may alert the user if the device performance exceeds or is near the limits on acceptable ranges for the rate or duration of shaking.
  • the device may have shaken the sample at a rate that was too high, too low, or close to the upper or lower limit on shaking rate. The device would alert the user of this potential concern.
  • the device will detect whether the sample is expired (e.g. by reading information from an indicator on the sample container). The device may alert the user of this and/or may prevent the device from operating while the expired sample is received by the device.
  • the device includes an indicator portion separate from the display that indicates to a user the sample type that has been detected.
  • the indicator may have lights that indicate sample type (e.g., aqueous or non-aqueous UCA formulation), or may have a display that displays the name of the sample type.
  • the device may ask the user to confirm the sample type that has been detected before the device can act on the sample.
  • the device may be powered by plugging into a wall outlet and/or may run on battery power.
  • the battery is rechargeable.
  • the holder includes a button or other sensor to detect whether a container has been appropriately received. In some cases, the device will not operate unless it detects a container in the holder.
  • the device may be connected to a computer or network, e.g. via Wi-Fi, USB, or other connection.
  • This connection may be used to remotely maintain the device, e.g. patching/upgrading software and/or monitoring the device status and usage.
  • the connection may also be used for data delivery, e.g., data obtained by the device may be sent to a database and/or printer.
  • the device may record and transmit information such as vial usage, shaking times, temperature and other conditions, device usage, analysis results, to a database or other data storage location.
  • information from the device may be compared with databases of information to detect abnormalities with the device or the sample, and/or the comparisons may be used to categorize the sample.
  • the device may count and monitor the amount of samples processed and/or the condition of the device and accordingly advise the user of a need to reorder items such as samples, device parts that require replacement, etc.
  • FIG. 1 depicts an illustrative schematic representing a device having a detector for reading an indicator from a sample container.
  • the device 1 includes a base 60 and a cover 70 .
  • the cover 70 is opened by rotationally pivoting the cover relative to the base.
  • the cover can be entirely lifted off and removed from the base.
  • the sample container 100 to be used with the device includes an indicator 110 that indicates the type of sample in the container.
  • the device includes a holder 10 for receiving and holding the sample container and a detector 30 for reading the indicator 110 .
  • the device also includes a shaking device 20 .
  • the device further includes a control panel 40 , which includes control buttons 41 and a display 44 .
  • the device may further include an indicator 50 separate from the display 44 .
  • the indicator 50 may include signals such as lights that indicate the sample type that has been detected.
  • the device 1 is used with a sample container 100 that includes an indicator in the form of a RFID tag 112 .
  • the device 1 includes an RFID reader 32 which is connected to the device via a wire 33 .
  • the sample container 100 is received by a holder 10 which is attached to a shaking arm 20 .
  • the device also includes a control panel 40 with a start button 42 and a cancel button 43 , as well as a display 44 .
  • the device also includes n indicator 50 with three lights 51 , 52 , 53 Corresponding to the three sample types. When the device detects a certain sample type, the light corresponding to that sample type lights up.
  • the device 1 is used with a sample container 100 that includes an indicator in the form of a bar code 114 .
  • the device 1 includes a bar code reader 34 which is connected to the device via a wire 35 .
  • the device 1 has a sample holder 10 that accommodates only a single container size and does not allow a larger container to fit.
  • the sample holder 10 may have a cap cover 21 to hold the vial in place.
  • the cap cover 21 may receive the cap of the vial and hold the vial via interference fit, a threaded arrangement (e.g. outer threads on the vial cap that mate with inner threads on the cap cover 21 ), mechanical interlock or any other suitable arrangement.
  • the sample holder 10 may have a spring 23 at the base of the holder to keep the vial from moving within the holder and partially eject the vial once the cap is removed for ease of removing the vial.
  • the holder 10 can expand to accommodate a larger container, and also detect the holder size to detect the sample type, as previously discussed.
  • the shaking device comprises a temperature sensor that measures the temperature of the UCA formulation and/or the vial containing the UCA formulation.
  • the device is set to operate only when the UCA formulation or the vial containing the UCA formulation is at or about room temperature.
  • Room temperature as used herein means a temperature of 15-30° C., including 18-25° C. and 20-25° C., and all temperatures therebetween.
  • Containers e.g., vials
  • the UCA formulations may be provided in a container (or housing).
  • the container is a vial.
  • the vial may be made of any material including but not limited to glass or plastic.
  • the glass may be pharmaceutical grade glass.
  • the container may be sealed with a stopper such as a rubber stopper.
  • the container is a 0.5-10 mL container.
  • the container may be a 1-5 mL container, or a 1 or 2 mL container.
  • Such volumes refer to the volume of liquid typically placed into the container (referred to as the liquid fill volume). This is in contrast to the entire internal volume of the container, which will be higher than the liquid fill volume.
  • liquid fill and internal volumes are as follows: Schott 2 mL (liquid fill volume) vial having a 2.9 mL internal volume; Schott 3 mL (liquid fill volume) vial having a 4.5 mL internal volume; and Wheaton 1 mL (liquid fill volume) v-vial having a 1.2 mL internal volume.
  • the internal volume of a container may be occupied with lipid formulation and gas.
  • a suitable container is the Wheaton 2 ml glass vial (commercially available from, for example, Nipro, Cat. No. 2702, B33BA, 2 cc, 13 mm, Type I, flint tubing vial), having an actual internal volume of about 3.75 ml.
  • An example of a suitable stopper is a West gray butyl lyo, siliconized stopper (Cat. No. V50, 4416/50, 13 mm, WS-842).
  • An example of a suitable seal is a West flip-off aluminum seal (Cat. No. 3766, white, 13 mm, 13-F-A-591).
  • the containers are preferably sterile and/or are sterilized after introduction of the lipid solution and/or gas as described in published PCT application WO99/36104.
  • the container is a flat bottom container such as a flat-bottom vial. Suitable vials include flat bottom borosilicate vials, including Wheaton vials.
  • the container is a non-flat bottom container or vial.
  • the container is a V-bottom container such as a V-bottom vial.
  • the container is a round-bottom container such as round-bottom vial.
  • the container has converging walls such that its bottom surface area (or bottom surface diameter) is smaller than its top (opening) surface area (or diameter) or smaller than any diameter therebetween (e.g., a body diameter).
  • a V-bottom container or vial has converging walls, and its bottom surface area is significantly smaller than any of its top or body surface areas.
  • UCA formulations comprise one and typically more than one lipid.
  • lipids or “total lipid” or “combined lipids” means a mixture of lipids.
  • the lipids may be provided in their individual solid state (e.g., powdered) forms. Alternatively, the lipids may be provided as a lipid blend. Methods of making a lipid blend include those described in U.S. Pat. No. 8,084,056 and published PCT application WO 99/36104.
  • a lipid blend, as used herein, is intended to represent two or more lipids which have been blended resulting in a more homogeneous lipid mixture than might otherwise be attainable by simple mixing of lipids in their individual powdered form.
  • the lipid blend is generally in a powder form.
  • a lipid blend may be made through an aqueous suspension-lyophilization process or an organic solvent dissolution-precipitation process using organic solvents. In the aqueous suspension-lyophilization process, the desired lipids are suspended in water at an elevated temperature and then concentrated by lyophilization.
  • the organic solvent dissolution method involves the following steps:
  • lipids e.g., DPPA, DPPC, and MPEG5000 DPPE
  • a first non-aqueous solvent system is typically a combination of solvents, for example CHCl 3 /MeOH, CH 2 Cl 2 /MeOH, and toluene/MeOH.
  • the first non-aqueous solvent is a mixture of toluene and methanol. It may be desirable to warm the lipid solution to a temperature sufficient to achieve complete dissolution. Such a temperature is preferably about 25 to 75° C., more preferably about 35 to 65° C. After dissolution, undissolved foreign matter may be removed by hot-filtration or cooling to room temperature and then filtering. Known methods of filtration may be used (e.g., gravity filtration, vacuum filtration, or pressure filtration).
  • the solution is then concentrated to a thick gel/semisolid. Concentration is preferably done by vacuum distillation. Other methods of concentrating the solution, such as rotary evaporation, may also be used.
  • the temperature of this step is preferably about 20 to 60° C., more preferably 30 to 50° C.
  • the thick gel/semisolid is then dispersed in a second non-aqueous solvent.
  • the mixture is slurried, preferably near ambient temperature (e.g., 15-30° C.) .
  • Useful second non-aqueous solvents are those that cause the lipids to precipitate from the filtered solution.
  • the second non-aqueous solvent is preferably methyl t-butyl ether (MTBE). Other ethers and alcohols may be used.
  • the solids produced upon addition of the second non-aqueous solvent are then collected.
  • the collected solids are washed with another portion of the second non-aqueous solvent (e.g., MTBE).
  • Collection may be performed via vacuum filtration or centrifugation, preferably at ambient temperature. After collection, it is preferred that the solids are dried in vacuo at a temperature of about 20-60° C.
  • the organic solvent dissolution-precipitation process is preferred over the aqueous suspension/lyophilization process for a number of reasons as outlined in U.S. Pat. No. 8,084,056 and published PCT application WO 99/36104, including the uniformly distributed lipid solid that results using the organic dissolution method.
  • the lipids may be provided as individual powders that are dissolved together or individually directly into propylene glycol, glycerol or propylene glycol/glycerol to form the non-aqueous mixture.
  • a lipid solution is a solution comprising a mixture of lipids.
  • a lipid formulation is a formulation comprising one or more lipids.
  • the lipids may be cationic, anionic or neutral lipids.
  • the lipids may be of either natural, synthetic or semi-synthetic origin, including for example, fatty acids, fluorinated lipids, neutral fats, phosphatides, oils, fluorinated oils, glycolipids, surface active agents (surfactants and fluorosurfactants), aliphatic alcohols, waxes, terpenes and steroids.
  • At least one of the lipids may be a phospholipid, and thus the lipid blend may be referred to as a phospholipid blend.
  • a phospholipid as used herein, is a fatty substance containing an oily (hydrophobic) hydrocarbon chain (s) with a polar (hydrophilic) phosphoric head group. Phospholipids are amphiphilic. They spontaneously form boundaries and closed microspheres in aqueous media.
  • lipids are phospholipids, preferably 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC); 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid (DPPA); and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine (DPPE).
  • DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine
  • DPPA 1,2-dipalmitoyl-sn-glycero-3-phosphatidic acid
  • DPPE 1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine
  • DPPA and DPPE may be provided as monosodium salt forms.
  • the lipid components may be modified in order to decrease the reactivity of the microsphere with the surrounding environment, including the in vivo environment, thereby extending its half-life.
  • Lipids bearing polymers such as chitin, hyaluronic acid, polyvinylpyrrolidone or polyethylene glycol (PEG), may also be used for this purpose.
  • Lipids conjugated to PEG are referred to herein as PEGylated lipids.
  • the PEGylated lipid is DPPE-PEG or DSPE-PEG
  • Conjugation of the lipid to the polymer such as PEG may be accomplished by a variety of bonds or linkages such as but not limited to amide, carbamate, amine, ester, ether, thioether, thioamide, and disulfide (thioester) linkages.
  • Terminal groups on the PEG may be, but are not limited to, hydroxy-PEG (HO-PEG) (or a reactive derivative thereof), carboxy-PEG (COOH-PEG), methoxy-PEG (MPEG), or another lower alkyl group, e.g., as in iso-propoxyPEG or t-butoxyPEG, amino PEG (NH2PEG) or thiol (SH-PEG).
  • HO-PEG hydroxy-PEG
  • COOH-PEG carboxy-PEG
  • MPEG methoxy-PEG
  • another lower alkyl group e.g., as in iso-propoxyPEG or t-butoxyPEG, amino PEG (NH2PEG) or thiol (SH-PEG).
  • the molecular weight of PEG may vary from about 500 to about 10000, including from about 1000 to about 7500, and from about 1000 to about 5000. In some important embodiments, the molecular weight of PEG is about 5000. Accordingly, DPPE-PEG5000 or DSPE-PEG5000 refers to DPPE or DSPE having attached thereto a PEG polymer having a molecular weight of about 5000.
  • the percentage of PEGylated lipids relative to the total amount of lipids in the lipid solution, on a molar basis, is at or between about 2% to about 20%. In various embodiments, the percentage of PEGylated lipids relative to the total amount of lipids is at or between 5 mole percent to about 15 mole percent.
  • the lipids are 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) , 1, 2-dipalmitoyl-sn-glycero-3-phosphatidic, mono sodium salt (DPPA), and N-(polyethylene glycol 5000 carbamoyl) -1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine, monosodium salt (PEG5000-DPPE).
  • the polyethylene glycol 5000 carbamoyl may be methoxy polyethylene glycol 5000 carbamoyl.
  • the lipids may be one, two or all three of DPPA, DPPC and PEG5000-DPPE.
  • PEG5000-DPPE may be MPEG5000-DPPE or HO-PEG5000-DPPE.
  • Suitable lipids include, for example, fatty acids, lysolipids, fluorinated lipids, phosphocholines, such as those associated with platelet activation factors (PAF) (Avanti Polar Lipids, Alabaster, Ala.), including 1-alkyl-2-acetoyl-sn-glycero 3-phosphocholines, and 1-alkyl-2-hydroxy-sn-glycero 3-phosphocholines; phosphatidylcholine with both saturated and unsaturated lipids, including dioleoylphosphatidylcholine; dimyristoyl-phosphatidylcholine; dipentadecanoylphosphatidylcholine; dilauroylphosphatdylcholine; 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DP
  • Suitable lipids include phosphatidylcholines, such as diolecylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine (DPPC), and distearoylphosphatidylcholine; phosphatidylethanolamines, such as dipalmitoylphosphatidylethanolamine (DPPE), dioleoylphosphatidylethanolamine and N-succinyl-dioleoylphosphatidylethanolamine; phosphatidylserines; phosphatidyl-glycerols; sphingolipids; glycolipids, such as ganglioside GM1; glucolipids; sulfatides; glycosphingolipids; phosphatidic acids, such as dipalmatoylphosphatidic acid (DPPA); palmitic fatty acids; stearic fatty acids; arachidonic fatty acids; lauric
  • DPPA, DPPC and DPPE their molar percentages may be about 77-90 mole % DPPC, about 5-15 mole % DPPA, and about 5-15 mole % DPPE, including DPPE-PEG5000.
  • Preferred ratios of each lipid include those described in the Examples section such as a weight % ratio of 6.0 to 53.5 to 40.5 (DPPA:DPPC:MPEG5000-DPPE) or a mole % ratio of 10 to 82 to 8 (10:82:8) (DPPA:DPPC:MPEG5000-DPPE).
  • the gas is preferably substantially insoluble in the lipid solutions provided herein.
  • the gas may be a non-soluble fluorinated gas such as sulfur hexafluoride or a perfluorocarbon gas.
  • perfluorocarbon gases include perfluoropropane, perfluoromethane, perfluoroethane, perfluorobutane, perfluoropentane, perfluorohexane.
  • gases that may be used in the microspheres of the invention are described in U.S. Pat. No. 5,656,211 and are incorporated by reference herein.
  • the gas is perfluoropropane.
  • gases include, but are not limited to, hexafluoroacetone, isopropylacetylene, allene, tetrafluoroallene, boron trifluoride, 1,2-butadiene, 1,3-butadiene, 1,2,3-trichlorobutadiene, 2-fluoro-1,3-butadiene, 2-methyl-1,3 butadiene, hexafluoro-1,3-butadiene, butadiyne, 1-fluorobutane, 2-methylbutane, decafluorobutane (perfluorobutane), decafluoroisobutane (perfluoroisobutane), 1-butene, 2-butene, 2-methy-l-butene, 3-methyl-1-butene, perfluoro-1-butene, perfluoro-1-butene, perfluoro-2-butene, 4-phenyl-3-butene-2-one, 2-methyl-1-butene
  • Fluorinated gases that is, a gas containing one or more fluorine molecules, such as sulfur hexafluoride
  • fluorocarbon gases that is, a fluorinated gas which is a fluorinated carbon or gas
  • perfluorocarbon gases that is, a fluorocarbon gas which is fully fluorinated, such as perfluoropropane and perfluorobutane
  • the gas such as the perfluorocarbon gas is typically present below its pure concentration at room temperature due to the incorporation of air during production.
  • concentration of perfluoropropane when present in a vial comprising a non-aqueous mixture and a gas headspace is expected to be about 6.52 mg/mL, at about one atmosphere of pressure.
  • concentrations of other gases, as known in the art, would be similarly diluted due to incorporation of air during production.
  • the gas such as perflutren gas
  • the gas may be injected into or otherwise added to the container (e.g., the vial) comprising the solution or into the solution itself in order to provide a gas other than air.
  • gases heavier than air may be added to a sealed or an unsealed container.
  • a gaseous precursor may also be used, followed by conversion of the precursor into a gas either by temperature or pressure change.
  • the invention provides methods of use of the UCA formulations provided herein. Once activated, the UCA formulations may be used in vivo in human or non-human subjects or in vitro.
  • the formulations provided herein may be used for diagnostic or therapeutic purposes or for combined diagnostic and therapeutic purposes.
  • the formulations When used as UCA for human subjects, the formulations are activated as described herein in order to form a sufficient number of gas-filled microspheres.
  • Such microspheres may be used directly (neat) or may be diluted further in a solution, including a pharmaceutically acceptable solution, and administered in one or more bolus injections or by a continuous infusion. Administration is typically intravenous injection. Imaging is then performed shortly thereafter.
  • the imaging application can be directed to the heart or it may involve another region of the body that is susceptible to ultrasound imaging. Imaging may be imaging of one or more organs or regions of the body including without limitation the heart, blood vessels, the cardiovasculature, the liver, the kidneys and the head.
  • Subjects of the invention include but are not limited to humans and animals. Humans are preferred in some instances. Animals include companion animals such as dogs and cats, and agricultural or prize animals such as but not limited to bulls and horses.
  • UCAs are administered in effective amounts.
  • An effective amount will be that amount that facilitates or brings about the intended in vivo response and/or application.
  • the effective amount may be an amount of lipid microspheres that allow imaging of a subject or a region of a subject.
  • a device in accordance with some embodiments may include a computer system including at least one processor programmed to perform identification of the container and/or its contents and upon determining the identification, determine appropriate actions to perform based on the identification.
  • FIG. 5 illustrates a flow chart of a process for selectively performing one or more actions to a vial placed within a device in accordance with some embodiments.
  • an identification of a sample type placed in the device is determined. Identification of the sample type may be determined in any suitable way, examples of which are described herein.
  • the device may present a user interface that enables a user to manually enter an identifier of the sample type.
  • the device may be configured to automatically determine the sample type identification by analyzing one or more indicators located on or associated with the vial or by analyzing one or more properties of the contents of the container.
  • the device may be configured to initially automatically identify the sample type, and if such an automatic identification fails the device may provide an error message and/or prompt a user of the device to manually enter the sample type identification.
  • a detector e.g., an RFID reader, an optical scanner, etc.
  • the device may include at least one storage device configured to store a look-up-table (LUT) or other data structure that stores information about the action(s) to be performed for particular sample type identifications. For example, a first set of actions may be performed if it is determined that the vial contains a first UCA formulation type and a second set of actions may be performed if it is determined that the vial contains a second UCA formulation type.
  • LUT look-up-table
  • the device may be configured to distinguish between containers with any number of different formulation types or substances contained therein, and embodiments are not limited in this respect.
  • the process proceeds to act 530 , where the at least one processor incorporated in the device instructs components of the device to perform the action(s) determined in act 520 .
  • the determination to perform the action(s) may be based, at least in part, on factors other than the identification of the sample type. For example, factors such as whether a lid of the device is closed or whether the device is in a particular operating state may be considered when determining whether to perform the action(s).
  • the at least one processor may communicate with the various components of the device to effectuate the performance of the determined action(s) in any suitable manner.
  • FIG. 6 illustrates a detailed flow chart of a process for determining action(s) to perform on a sample in a vial by using RFID identification in accordance with an embodiment described in more detail below.
  • the device reads the RFID tag to identify the container as containing a first UCA formulation type (DEFINITY®) or a second UCA formulation type (DEFINITY-II). Based on the identification and other conditions being met, the device is activated for a particular amount of time.
  • a first UCA formulation type DEFINITY®
  • DEFINITY-II second UCA formulation type
  • the computer system 800 may include one or more processors 710 and one or more computer-readable tangible non-transitory storage media (e.g., memory 720 , one or more non-volatile storage media 730 , or any other suitable storage device).
  • the processor 710 may control writing data to and reading data from the memory 720 and the non-volatile storage device 730 in any suitable manner, as the aspects of the present invention described herein are not limited in this respect.
  • the processor 710 may execute one or more instructions stored in one or more computer-readable storage media (e.g., the memory 720 ), which may serve as tangible non-transitory computer-readable storage media storing instructions for execution by the processor 710 .
  • computer-readable storage media e.g., the memory 720
  • the processor 710 may execute one or more instructions stored in one or more computer-readable storage media (e.g., the memory 720 ), which may serve as tangible non-transitory computer-readable storage media storing instructions for execution by the processor 710 .
  • the above-described embodiments of the present invention may be implemented in any of numerous ways.
  • the embodiments may be implemented using hardware, software or a combination thereof.
  • the software code can be executed on any suitable processor or collection of processors, whether provided in a single computer or distributed among multiple computers.
  • any component or collection of components that perform the functions described above can be generically considered as one or more controllers that control the above-discussed functions.
  • the one or more controllers can be implemented in numerous ways, such as with dedicated hardware, or with general purpose hardware (e.g., one or more processors) that is programmed using microcode or software to perform the functions recited above.
  • one implementation of the embodiments of the present invention comprises at least one non-transitory computer-readable storage medium (e.g., a computer memory, a USB drive, a flash memory, a compact disk, a tape, etc.) encoded with a computer program (i.e., a plurality of instructions), which, when executed on a processor, performs the above-discussed functions of the embodiments of the present invention.
  • the computer-readable storage medium can be transportable such that the program stored thereon can be loaded onto any computer resource to implement the aspects of the present invention discussed herein.
  • references to a computer program which, when executed, performs the above-discussed functions is not limited to an application program running on a host computer. Rather, the term computer program is used herein in a generic sense to reference any type of computer code (e.g., software or microcode) that can be employed to program a processor to implement the above-discussed aspects of the present invention.
  • DEFINITY® Liantheus Medical Imaging, Inc.
  • an active form (“activated”) by mechanical shaking (described in U.S. Pat. No. 6,039,557, the contents of which are hereby incorporated by reference and may be used in the present process) of the PFP/lipid solution using a VIALMIX®.
  • Optimal VIALMIX® activation of DEFINITY® consistently produces gas filled microspheres that can be analyzed for number and size distribution using a particle sizer (Malvern FPIA-3000 Sysmex) when diluted with saline having lower and upper cutoffs of 1 and 80 microns.
  • a particle sizer Mervern FPIA-3000 Sysmex
  • DEFINITY® was activated for different periods of time and DEFINITY-II was activated for 75 seconds and the effects on microsphere mean diameter and concentration were analyzed.
  • Vials (Nipro Glass Americas, Nipro, Cat. No. 2702, B33BA, 2 cc, 13 mm, Type I, flint tubing vial) containing aqueous based UCA formulation (DEFINITY®) or containing non-aqueous UCA formulation (DEFINITY-II) were activated using a VIALMIX®.
  • the microspheres formed were analyzed after reconstitution for number and size distribution using a particle sizer (Malvern FPIA-3000 Sysmex) when diluted with saline having lower and upper cutoffs of 1 and 80 microns. The activation times to achieve optimal microsphere number and equivalent diameter were different for the two products.
  • Activation of DEFINITY® with the longer (75 sec) vs. the recommended 45 sec shake resulted in a markedly lower microsphere count but similar mean diameter. (see Tables 1 and 2).
  • a device which could differentiate and activate with the correct shaking period A) vials with appropriate RFID tagged aqueous based UCA formulation (DEFINITY®), B) vials with appropriately RFID tagged non-aqueous UCA formulation (DEFINITY-II) or C) vials with no tag or wrong tag was created by modifying a VIALMIX®.
  • a diagram showing the front panel of the device is depicted in FIG. 2 .
  • the operation described in the next paragraph was effected using an RFID tag reader mounted on the interior of the device cover in close proximity to the vial holder, combined with an ATmega328P microcontroller to read RFID tags on vials in the holder and either enable or inhibit the operation of the device based on the presence or absence of a tag with a recognized unique identifier (UID) number.
  • the RFID reader used incorporates a MFRC522 integrated circuit that is compliant with ISO/IEC 14443A standards.
  • the tags used are “MIFARE Ultralite” in the form of self-sticking 50 ⁇ 15 mm labels operating at 13.56 MHz.
  • the device To activate a vial of DEFINITY® (or DEFINITY-II), the device is first turned on using the rear panel rocker switch, the cover opened and the vial is mounted in the vial holder as specified in the VIALMIX® operating instructions.
  • the RFID tag reader is incorporated into the VIALMIX® wiring such that the shaker can only be “started” by closing the cover combined with the RFID reader identifying an appropriate tag.
  • a green front panel LED labeled “DEFINITY®” is illuminated, and pressing the front panel “start” button initiates activation for a standard 45 second period.
  • a green front panel LED labeled “DEFINITY-II” is illuminated, and pressing the front panel “start” button initiates activation for a total of 75 seconds (the standard 45 second period followed by an additional activation period of 30 seconds).
  • a red LED labeled “other” is illuminated and pressing the “start” button on the front panel does not initiate activation.
  • no LED is illuminated and once again pressing the “start” button on the front panel does not initiate activation.
  • the “DEFINITY-II” LED was illuminated and the vial activated.
  • the non-aqueous contrast agent was reconstituted with 0.9% saline and subsequently analyzed for particle number and size using a Malvern FPIA-3000 Sysmex. The testing demonstrated both DEFINITY® and DEFINITY-II bearing the appropriate RFID tag could be activated.
  • the microsphere size was very similar to DEFINITY® and the total microsphere count approximately 1.8 fold higher.
  • VIALMIX® modified for RFID recognition with RFID-tagged label vials is illustrated in FIG. 2 .
  • a device which could differentiate and activate with the correct shaking period A) vials with appropriate barcoded aqueous-based UCA formulation (DEFINITY®), B) vials with appropriately barcoded non-aqueous UCA formulation (DEFINITY-II) or C) vials with no barcode or wrong barcode was created by modifying a VIALMIX®.
  • a diagram showing the front panel of the device is depicted in FIG. 3 .
  • the operation described in the next paragraph was effected using a barcode scanner in close proximity to the vial holder, combined with a computer to read barcodes on vials in the holder and either enable or inhibit the operation of the device based on the presence or absence of a barcode with a recognized identification number.
  • the barcode scanner used was a standard keyboard-mimicking device connected via USB. Barcodes for demonstration purposes were generated online using the web site barcodesinc, generator, index.php.
  • the device To activate a vial of DEFINITY® or DEFINITY-II, the device is first turned on using the rear panel rocker switch, the cover opened and the vial is mounted in the vial holder as specified in the operating instructions.
  • the barcode scanner is incorporated into the VIALMIX® wiring such that the shaker can only be “started” by both closing the cover and having the barcode scanner identify an appropriate barcode label.
  • pressing the front panel “start” button initiates activation.
  • pressing the front panel “start” button also initiates activation.
  • pressing the “start” button on the front panel does not initiate activation.
  • pressing the “start” button on the front panel does not initiate activation.
  • VIALMIX® modified for line/barcode scanner recognition with barcode-labeled (or tagged) vials is illustrated in FIG. 3 .
  • a device which could differentiate A) vials containing aqueous based UCA formulation (DEFINITY®), from B) vials containing non-aqueous UCA formulation (DEFINITY-II) was created by modifying the vial holder on a VIALMIX® shaking device.
  • the vial holder arm on the VIALMIX® device was modified to allow a vial of limited dimensions to be held, shaken and activated to acceptable product specifications while at the same time not allowing a larger vial to fit.
  • the differentiation of the vials was achieved by designing a holder tube to be attached to the shaker arm with a diameter that would fit a smaller vial (Schott, West Pharmaceuticals, #6800-0314) however not the larger commercial DEFINITY® vial (Nipro Glass Americas, Nipro, Cat. No. 2702, B33BA, 2 cc, 13 mm, Type I, flint tubing vial), for example.
  • a diagram showing the vial holder is shown in FIG. 4 .
  • the non-aqueous UCA formulation was manufactured and filled into the smaller Schott vial.
  • VIALMIX® modified to hold vials of different shape and/or size is illustrated in FIG. 4 .
  • a device that could be used to change the speed of DEFINITY® and DEFINITY-II shaking was developed by replacing the AC motor in a VialMix with a Brushless DC motor (Trinamic QBL4208-100-04-025) and using a controller (TMCM-1640) and Velleman Inc. 24 volt DC power supply to control activation speed and time.
  • vials Nipro Glass Americas, Nipro, Cat. No. 2702, B33BA, 2 cc, 13 mm, Type I, flint tubing vial
  • vials Nipro Glass Americas, Nipro, Cat. No. 2702, B33BA, 2 cc, 13 mm, Type I, flint tubing vial
  • aqueous-based UCA formulation DEFINITY®
  • DEFINITY-II non-aqueous UCA formulation
  • microspheres formed were analyzed after reconstitution for number and size distribution using a particle sizer (Malvern FPIA-3000 Sysmex) having lower and upper cutoffs of 1 and 80 microns.
  • the activation times for different shake speeds to achieve optimal microsphere number and equivalent diameter were different for the two products.
  • increasing the shake speed decreased the time (see Tables 5 and 6).
  • the longer shake time required for DEFINITY-II compared to DEFINITY® could be overcome by a small increase in the shake speed.
  • the DEFINITY® shake time could be decreased by increasing the shake speed.
  • inventive embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed.
  • inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein.
  • a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
  • the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
  • This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified.
  • “at least one of A and B” can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Acoustics & Sound (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Software Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Mixers With Rotating Receptacles And Mixers With Vibration Mechanisms (AREA)
  • Accessories For Mixers (AREA)
US15/587,368 2016-05-04 2017-05-04 Methods and devices for preparation of ultrasound contrast agents Abandoned US20170319718A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/587,368 US20170319718A1 (en) 2016-05-04 2017-05-04 Methods and devices for preparation of ultrasound contrast agents
US16/559,528 US10588988B2 (en) 2016-05-04 2019-09-03 Methods and devices for preparation of ultrasound contrast agents
US16/780,328 US20200171177A1 (en) 2016-05-04 2020-02-03 Methods and devices for preparation of ultrasound contrast agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662331968P 2016-05-04 2016-05-04
US201662332462P 2016-05-05 2016-05-05
US15/587,368 US20170319718A1 (en) 2016-05-04 2017-05-04 Methods and devices for preparation of ultrasound contrast agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/559,528 Continuation US10588988B2 (en) 2016-05-04 2019-09-03 Methods and devices for preparation of ultrasound contrast agents

Publications (1)

Publication Number Publication Date
US20170319718A1 true US20170319718A1 (en) 2017-11-09

Family

ID=60203645

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/587,368 Abandoned US20170319718A1 (en) 2016-05-04 2017-05-04 Methods and devices for preparation of ultrasound contrast agents
US16/559,528 Active US10588988B2 (en) 2016-05-04 2019-09-03 Methods and devices for preparation of ultrasound contrast agents
US16/780,328 Pending US20200171177A1 (en) 2016-05-04 2020-02-03 Methods and devices for preparation of ultrasound contrast agents

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/559,528 Active US10588988B2 (en) 2016-05-04 2019-09-03 Methods and devices for preparation of ultrasound contrast agents
US16/780,328 Pending US20200171177A1 (en) 2016-05-04 2020-02-03 Methods and devices for preparation of ultrasound contrast agents

Country Status (12)

Country Link
US (3) US20170319718A1 (de)
EP (1) EP3452108A4 (de)
JP (2) JP2019515936A (de)
KR (2) KR20180133527A (de)
CN (2) CN115531560B (de)
AU (1) AU2017260532A1 (de)
BR (1) BR112018072342A2 (de)
CA (1) CA3022698A1 (de)
IL (2) IL262647B2 (de)
MX (1) MX2018013409A (de)
TW (2) TWI832081B (de)
WO (1) WO2017192910A2 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022460B2 (en) 2014-12-31 2018-07-17 Lantheus Medical Imaging, Inc. Lipid-encapsulated gas microsphere compositions and related methods
US10220104B2 (en) 2016-07-06 2019-03-05 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US10588988B2 (en) 2016-05-04 2020-03-17 Lantheus Medical Imaging, Inc. Methods and devices for preparation of ultrasound contrast agents

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200360289A1 (en) 2019-05-15 2020-11-19 Bracco Suisse Sa Freeze-dried product and gas-filled microvesicles suspension
US11717570B2 (en) 2019-05-15 2023-08-08 Bracco Suisse Sa Gas-filled microvesicles
US20230270412A1 (en) * 2020-08-04 2023-08-31 Lantheus Medical Imaging, Inc. Methods and devices for preparation of ultrasound contrast agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US20100089803A1 (en) * 2008-10-10 2010-04-15 Leroy Sina Lavi System and method for sorting specimen
US20120035063A1 (en) * 2009-04-17 2012-02-09 Curiox Biosystems Pte Ltd. Use of Chemically Patterned Substrate for Liquid Handling, Chemical and Biological Reactions

Family Cites Families (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873564A (en) 1971-03-03 1975-03-25 Synvar Ass 2-Imidazolinyl-3-oxide-1-oxypropionic acid
CH588887A5 (de) 1974-07-19 1977-06-15 Battelle Memorial Institute
CH621479A5 (de) 1977-08-05 1981-02-13 Battelle Memorial Institute
CH624011A5 (de) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4276885A (en) 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
AU545866B2 (en) 1980-11-17 1985-08-01 Schering Aktiengesellschaft Microbubble precursors and methods for their production and use
DE3141641A1 (de) 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
SE463651B (sv) 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
EP0158441B2 (de) 1984-03-08 2001-04-04 Phares Pharmaceutical Research N.V. Liposombildende Zusammensetzung
EP0231091B1 (de) 1986-01-24 1993-03-31 Children's Hospital Medical Center Stabile Emulsionen von stark fluorierten, organischen Verbindungen
JPS6360943A (ja) 1986-09-01 1988-03-17 Green Cross Corp:The 超音波診断造影剤
FR2634375B3 (fr) 1988-06-30 1991-07-05 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles de lipide amphiphiles sous forme de liposomes submicroniques
FR2608942B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
US5219538A (en) 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
JPS63277618A (ja) 1987-03-31 1988-11-15 Noebia:Kk リポソ−ムの製造方法
CH672733A5 (de) 1987-05-22 1989-12-29 Bracco Ind Chimica Spa
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
DE3803972A1 (de) 1988-02-05 1989-08-10 Schering Ag Ultraschallkontrastmittel
DE3812816A1 (de) 1988-04-16 1989-11-02 Lawaczeck Ruediger Dipl Phys P Verfahren zur solubilisierung von liposomen und/oder biologischer membranen sowie deren verwendung
US5171755A (en) 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
US5045304A (en) 1988-08-31 1991-09-03 Wayne State University Contras agent having an imaging agent coupled to viable granulocytes for use in magnetic resonance imaging of abscess and a method of preparing and using same
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5114703A (en) 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
FR2649335B1 (fr) 1989-07-05 1991-09-20 Texinfine Sa Procede et dispositif de production directe de liposomes
US5843473A (en) 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5228446A (en) 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5149319A (en) 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5705187A (en) 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5209720A (en) 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5776429A (en) 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US6088613A (en) 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5773024A (en) 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5088499A (en) 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5334381A (en) 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5352435A (en) 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
IN172208B (de) 1990-04-02 1993-05-01 Sint Sa
US5358702A (en) 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging
EP0526503B1 (de) 1990-04-10 1997-06-04 Imarx Pharmaceutical Corp. Polymere und ihre verwendung als kontrastmittel bei der bilderzeugung mit magnetischer resonanz
US5368840A (en) 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
IS1685B (is) 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
DE69233119T2 (de) 1991-06-18 2004-05-13 Imarx Pharmaceutical Corp., Tucson Neue liposomale arzneimittelfreisetzungssysteme
MX9205298A (es) 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
US5409688A (en) 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
WO1993005819A1 (en) 1991-09-17 1993-04-01 Sonus Pharmaceuticals, Inc Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media
WO1993006869A1 (en) 1991-10-04 1993-04-15 Mallinckrodt Medical, Inc. Gaseous ultrasound contrast agents
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
US5558855A (en) 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
ATE200985T1 (de) 1993-01-25 2001-05-15 Sonus Pharma Inc Phase-stift kolloide zur verwendung als ultraschallkontrastmittel
GB9305349D0 (en) 1993-03-16 1993-05-05 Nycomed Imaging As Improvements in or relating to contrast agents
GB9305351D0 (en) 1993-03-16 1993-05-05 Nycomed Imaging As Improvements in or relating to contrast agents
DE4313402A1 (de) 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermale Wirkstoffzubereitung
US5853755A (en) 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
JP3559849B2 (ja) 1993-07-30 2004-09-02 アイエムシーオーアール ファーマシューティカル カンパニー 超音波技術のための安定化された微小気泡組成物
GB9318288D0 (en) 1993-09-03 1993-10-20 Nycomed Imaging As Improvements in or relating to contrast agents
EP0717617B1 (de) 1993-09-09 2000-10-25 Schering Aktiengesellschaft Wirkstoffe und gas enthaltende mikropartikel
CA2153251C (en) 1993-11-05 1998-09-01 David Samuel Collins Liposome preparation and material encapsulation method
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
CN1068229C (zh) 1993-12-15 2001-07-11 勃勒柯研究有限公司 超声对比介质、含该介质的对比剂及方法
NO940711D0 (no) 1994-03-01 1994-03-01 Nycomed Imaging As Preparation of gas-filled microcapsules and contrasts agents for diagnostic imaging
US5776488A (en) 1994-03-11 1998-07-07 Yoshitomi Pharmaceutical Industries, Ltd. Liposome preparation
CN1148812A (zh) 1994-03-28 1997-04-30 尼科梅德成像有限公司 “脂质体”
US5736121A (en) 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US6066331A (en) 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
US5562893A (en) 1994-08-02 1996-10-08 Molecular Biosystems, Inc. Gas-filled microspheres with fluorine-containing shells
JPH08151335A (ja) 1994-09-27 1996-06-11 Otsuka Pharmaceut Co Ltd 超音波造影剤およびその製造方法
US5540909A (en) 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5558092A (en) 1995-06-06 1996-09-24 Imarx Pharmaceutical Corp. Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
EP0831932B1 (de) 1995-06-07 2004-05-06 Imarx Pharmaceutical Corp. Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
US5897851A (en) 1995-06-07 1999-04-27 Sonus Pharmaceuticals, Inc. Nucleation and activation of a liquid-in-liquid emulsion for use in ultrasound imaging
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
JP2001507207A (ja) 1996-05-01 2001-06-05 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 化合物を細胞に送達する方法
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US5837221A (en) 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
ES2289188T3 (es) 1996-09-11 2008-02-01 Bristol-Myers Squibb Medical Imaging, Inc. Procedimiento para la obtencion de imagenes para el diagnostico usando un agente de contraste y un vasodilatador.
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
DE69721331T2 (de) 1996-10-21 2004-05-06 Amersham Health As Verbesserungen für oder in bezug auf kontrastmitteln in ultraschallbilddarstellung
AU733477B2 (en) 1996-10-28 2001-05-17 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
WO1998018498A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
EP0973552B1 (de) 1996-10-28 2006-03-01 Amersham Health AS Verbesserungen an oder in verbindung mit diagnotischen/therapeutischen verbindungen
WO1998018495A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
GB9717588D0 (en) 1997-08-19 1997-10-22 Nycomed Imaging As Improvements in or relating to contrast agents
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
ES2244169T3 (es) 1998-02-09 2005-12-01 Bracco International B.V. Suministro direccionado de medios biologicamente activos.
US6572840B1 (en) 1999-07-28 2003-06-03 Bristol-Myers Squibb Pharma Company Stable microbubbles comprised of a perfluoropropane encapsulated lipid moiety for use as an ultrasound contrast agent
US6943692B2 (en) 2001-02-02 2005-09-13 Bristol-Myers Squibb Pharma Company Apparatus and methods for on-line monitoring of fluorinated material in headspace of vial
US20030044354A1 (en) 2001-08-16 2003-03-06 Carpenter Alan P. Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2005063305A1 (en) * 2003-12-22 2005-07-14 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
WO2006028959A2 (en) 2004-09-03 2006-03-16 Imarx Therapeutics, Inc. Apparatus and method to prepare a microsphere-forming composition
BRPI0622087A2 (pt) 2005-04-06 2011-07-12 Mallinckrodt Inc sistemas e métodos para o gerenciamento de informações referentes a fluidos médicos e recipientes para os mesmos
EP1736113B1 (de) 2005-06-03 2009-08-05 3M Innovative Properties Company Dentalmaterialverarbeitungssystem und Kommunikationsverfahren
EP1834603A1 (de) 2006-03-10 2007-09-19 3M Innovative Properties Company Vorrichtung und Verfahren zur Ausgabe von zahnärztlichem Material
CN101229382A (zh) 2008-02-04 2008-07-30 许川山 一种适用于多种成像模式的新型造影剂
JP2012213475A (ja) * 2011-03-31 2012-11-08 Panasonic Corp 超音波造影剤注入装置
US9101895B2 (en) * 2011-04-15 2015-08-11 General Electric Company System for mixing and dispersing microbubble pharmaceuticals
US10279053B2 (en) 2011-07-19 2019-05-07 Nuvox Pharma Llc Microbubble compositions, method of making same, and method using same
US20130123781A1 (en) * 2011-08-24 2013-05-16 California Institute Of Technology Targeting microbubbles
JP2015002752A (ja) * 2011-12-09 2015-01-08 パナソニック株式会社 薬剤容器
WO2014015186A1 (en) * 2012-07-18 2014-01-23 Labminds Ltd. Automated solution dispenser
CN105008006B (zh) * 2013-02-11 2019-08-09 安德鲁·E·布洛什 用于提供非对称振荡的装置和方法
US10577554B2 (en) * 2013-03-15 2020-03-03 Children's Medical Center Corporation Gas-filled stabilized particles and methods of use
EP3570040B1 (de) * 2013-04-05 2024-02-14 F. Hoffmann-La Roche AG Analyseverfahren für eine biologische probe
TWI552761B (zh) 2013-05-03 2016-10-11 博信生物科技股份有限公司 一種脂質微／奈米氣泡、及其最佳化之製備方法及製備裝置
GB201405735D0 (en) * 2014-03-31 2014-05-14 Ge Healthcare As Ultrasound precursor preparation method
JP6594909B2 (ja) 2014-06-12 2019-10-23 エヴァン， シー． アンガー， リン脂質組成物、その凍結乾燥方法および凍結乾燥物
US20170360966A1 (en) 2014-10-30 2017-12-21 Lantheus Medical Imaging, Inc. Lipid encapsulated gas microsphere compositions and related methods
NZ733010A (en) 2014-12-31 2023-01-27 Lantheus Medical Imaging Inc Lipid-encapsulated gas microsphere compositions and related methods
IL262647B2 (en) 2016-05-04 2023-03-01 Lantheus Medical Imaging Inc Methods and devices for preparing sharpness factors for ultrasound
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US20100089803A1 (en) * 2008-10-10 2010-04-15 Leroy Sina Lavi System and method for sorting specimen
US20120035063A1 (en) * 2009-04-17 2012-02-09 Curiox Biosystems Pte Ltd. Use of Chemically Patterned Substrate for Liquid Handling, Chemical and Biological Reactions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Almansouri et al. Alternative power source for dental hygiene device. 2012 Project Proposal, Department of Mechanical Engineering Northern Arizona University. Available online at cefns.nau.edu/capstone/projects/ME/2013/Concussion/report4.pdf. Accessed 29 October 2018. (Year: 2012) *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022460B2 (en) 2014-12-31 2018-07-17 Lantheus Medical Imaging, Inc. Lipid-encapsulated gas microsphere compositions and related methods
US10583207B2 (en) 2014-12-31 2020-03-10 Lantheus Medical Imaging, Inc. Lipid-encapsulated gas microsphere compositions and related methods
US11395856B2 (en) 2014-12-31 2022-07-26 Lantheus Medical Imaging, Inc. Lipid-encapsulated gas microsphere compositions and related methods
US10588988B2 (en) 2016-05-04 2020-03-17 Lantheus Medical Imaging, Inc. Methods and devices for preparation of ultrasound contrast agents
US10220104B2 (en) 2016-07-06 2019-03-05 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US10583208B2 (en) 2016-07-06 2020-03-10 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11266749B2 (en) 2016-07-06 2022-03-08 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11266750B2 (en) 2016-07-06 2022-03-08 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11344636B2 (en) 2016-07-06 2022-05-31 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11529431B2 (en) 2016-07-06 2022-12-20 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11857646B2 (en) 2016-07-06 2024-01-02 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US11925695B2 (en) 2016-07-06 2024-03-12 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents

Also Published As

Publication number Publication date
BR112018072342A2 (pt) 2019-02-19
AU2017260532A1 (en) 2018-11-22
CN109641068A (zh) 2019-04-16
MX2018013409A (es) 2019-07-08
KR20180133527A (ko) 2018-12-14
WO2017192910A3 (en) 2017-12-28
IL262647A (en) 2018-12-31
CN115531560B (zh) 2024-05-17
IL262647B2 (en) 2023-03-01
TWI832081B (zh) 2024-02-11
JP2019515936A (ja) 2019-06-13
US20200000943A1 (en) 2020-01-02
IL296876A (en) 2022-12-01
CN109641068B (zh) 2022-09-30
TW202222260A (zh) 2022-06-16
EP3452108A4 (de) 2019-12-25
TW201800082A (zh) 2018-01-01
EP3452108A2 (de) 2019-03-13
CA3022698A1 (en) 2017-11-09
KR20220165808A (ko) 2022-12-15
TWI740937B (zh) 2021-10-01
US20200171177A1 (en) 2020-06-04
IL262647B (en) 2022-11-01
US10588988B2 (en) 2020-03-17
CN115531560A (zh) 2022-12-30
JP2022163011A (ja) 2022-10-25
WO2017192910A2 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
US10588988B2 (en) Methods and devices for preparation of ultrasound contrast agents
US20220395590A1 (en) Lipid-encapsulated gas microsphere compositions and related methods
US20230270412A1 (en) Methods and devices for preparation of ultrasound contrast agents
EA042049B1 (ru) Способы и устройства для получения контрастных средств для ультразвукового исследования

Legal Events

Date Code Title Description
AS Assignment

Owner name: LANTHEUS MEDICAL IMAGING, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROBINSON, SIMON P.;WALKER, CAROL;ONTHANK, DAVID C.;AND OTHERS;SIGNING DATES FROM 20170526 TO 20170601;REEL/FRAME:042833/0912

AS Assignment

Owner name: JPMORGAN CHASE BANK, N.A., NEW YORK

Free format text: PATENT SECURITY AGREEMENT;ASSIGNOR:LANTHEUS MEDICAL IMAGING, INC.;REEL/FRAME:045929/0908

Effective date: 20180411

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

AS Assignment

Owner name: LANTHEUS MEDICAL IMAGING, INC., MASSACHUSETTS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A.;REEL/FRAME:049623/0123

Effective date: 20190627

AS Assignment

Owner name: WELLS FARGO BANK, N.A., NORTH CAROLINA

Free format text: SECURITY AGREEMENT;ASSIGNOR:LANTHEUS MEDICAL IMAGING, INC.;REEL/FRAME:049628/0001

Effective date: 20190627

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: LANTHEUS MEDICAL IMAGING, INC., MASSACHUSETTS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:WELLS FARGO BANK, N.A.;REEL/FRAME:062047/0925

Effective date: 20221202